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Abstract  
According to 2013/59/Euratom BSS, for all medical exposure of patients for 
radiotherapeutic purposes, including Nuclear Medicine, doses in target volumes shall 
be individually planned. Furthermore, doses to non-target volumes (e.g. organs-at-risk) 
shall be as-low-as-reasonably-achievable and consistent with the intended 
radiotherapeutic purposes. For 90Y-microspheres radioembolization, four methods of 
activity calculation to be administered are usually used. For resin microspheres are 
presented three: empirical, body-surface-area (BSA) and partition methods. For glass 
microspheres application, only an activity calculation method is available. 
The 99mTc-MAA is primarily used for LSF analysis and evaluation of extrahepatic 
deposition, with the aim to predict intrahepatic post-therapy 90Y-microspheres 
distribution. Usually performed by planar and SPECT/CT imaging. In addition, 
treatment efficacy of radioembolization is assessed by the 90Y Bremsstrahlung SPECT 
imaging. However, Bremsstrahlung SPECT imaging demonstrates a poor image 
quality. 
A total of sixty two patients were evaluated for radioembolization after the 99mTc-MAA 
procedure and were treated with resin microspheres using the BSA method for activity 
calculation. A retrospective evaluation indicates that more than 35% of the treated 
patients have hepatocellular carcinoma. This analysis also indicates that a large 
number of patients did not present a significant LSF (approximately 80%), and the 
average of resin microspheres activity was about 1.70 ± 0.42 GBq. However, the three 
cases analyzed show the limitation of the currently used BSA activity calculation 
method compared with a partition method.  
In conclusion, caution regarding patient selection, treatment preparation including an 
appropriate dosimetry, and performance is particularly important to prevent toxicity to 
be associated with this treatment. Thus, the shift towards personalized radionuclide 
therapy should be the way forward. 
 
 
Keywords: Radioembolization; 90Y; Internal dosimetry; Nuclear Medicine; 
Radiotherapy 
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Resumo  
De acordo com a diretiva 2013/59/Euratom, para todas as exposições médicas de 
pacientes com fins radioterapêuticos, incluindo a Medicina Nuclear, as doses em 
volumes alvo devem ser planeadas individualmente. Além disso, as doses para 
volumes não visados (por exemplo, órgãos de risco) devem ser tão baixas quanto 
razoavelmente possível e consistentes com os propósitos radioterapêuticos 
pretendidos. Para a radioembolização com microesferas de 90Y, são utilizados 
geralmente quatro métodos de cálculo de atividade a ser administrada. Para as 
microesferas de resina são apresentados três: método empírico, método do BSA e 
método de partição. Para a aplicação de microesferas de vidro, apenas um método de 
cálculo de atividade está disponível. 
99mTc-MAA é utilizado principalmente para análise de LSF e avaliação de deposição 
extra-hepática, com o objetivo de prever a distribuição intra-hepática de pós-terapia 
com microesferas de 90Y. Geralmente realizado através de imagens planar e 
SPECT/CT. Além disso, a eficácia do tratamento da radioembolização é avaliada pela 
imagem SPECT de 90Y Bremsstrahlung. No entanto, a imagem SPECT de 
Bremsstrahlung demonstra uma baixa qualidade de imagem. 
Um total de sessenta e dois pacientes foram avaliados para radioembolização após o 
procedimento de 99mTc-MAA e foram tratados com microesferas de resina usando o 
método BSA para o cálculo de atividade. Uma avaliação retrospectiva indica que mais 
de 35% dos pacientes tratados apresentam carcinoma hepatocelular. Esta análise 
também indica que um grande número de pacientes não apresentou LSF significativo 
(aproximadamente 80%), e a média da atividade administrada de microesferas de 
resina foi de cerca de 1,70 ± 0,42 GBq. No entanto, os três casos analisados mostram 
uma limitação do método BSA para o cálculo da atividade em comparação com um 
método de partição. 
Em conclusão, o cuidado com a seleção do paciente, a preparação do tratamento, 
com uma dosimetria apropriada, e o desempenho são particularmente importantes 
para evitar que a toxicidade seja associada a este tratamento. Assim, a mudança para 
a terapia personalizada com radionuclídeos deve ser o caminho a seguir. 
Palavras-chave: Radioembolização; 90Y, Dosimetria interna; Medicina Nuclear, 
Radioterapia  
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1. Introduction   
1.1. Dissertation Context 
Liver cancer, from metastatic cancer to hepatocellular carcinoma (HCC), is a highly 
fatal disease being the second most common cause of death from cancer in the world 
1. More than 700,000 new liver cancer cases throughout the world and accounting for 
more than 600,000 deaths occurred worldwide each year 2.  
One HCC option of treatment, being proposed to certain patients as a locoregional 
treatment, involves either chemoembolization or radioembolization. Radioembolization 
is based on the administration of a large quantity of microspheres labeled with yttrium-
90 (90Y) in the arterial vasculature of the liver, commonly known as selective internal 
radiation therapy (SIRT), reaching (and depositing a required dose) the tissues 
intended to be treated 3,4. The 90Y transarterial radioembolization is a complex 
technique and requires a multidisciplinary approach to planning, delivering and 
reviewing cancer treatment 5. 
According to 2013/59/Euratom BSS: For all medical exposure of patients for 
radiotherapeutic purposes, exposures of target volumes shall be individually planned 
and their delivery appropriately verified taking into account that doses to non-target 
volumes and tissues shall be as low as reasonably achievable and consistent with the 
intended radiotherapeutic purpose of the exposure. That is, to ensure the safe use of 
radioactively labeled drugs in medical practice, it is necessary to determine the 
radiation dose received by the patient (specially the treatment volume, sparing the 
healthy tissues) 6. For 90Y-microspheres radioembolization, four different models are 
available for planning the radiation activity for the tumor. For resin microspheres, the 
previously used activity calculation method was the empiric method. The empirical 
method is based uniquely on percentage of tumor mass, without any other patient-
based factor. The second method, the body surface area (BSA), is the semiempiric 
method. This is the most widely used methodology for determination the amount of 90Y-
microspheres activity to be administrated to patients and is relatively simple, not taking 
into account significant variations such as tumor size, shape or location. This model 
assumes that the size of each patient‘s liver correlates with the BSA. A third, more 
sophisticated method is the partition method. It is based on tumor and normal liver 
volumes and expected activity distribution, predicted by single photon emission 
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computed tomography (SPECT) imaging. The partition model is more accurate, 
scientifically rigorous and personalized, but less popular due to its relative complexity. 
For glass microspheres application, only an activity calculation method is available 7–9.  
A simulation of the real treatment is performed prior radioembolization with technetium-
99m-macroaggregated albumin (99mTc-MAA). 99mTc-MAA allows that planar and 
SPECT gamma-camera imaging and it is used to calculate the lung shunt fraction 
(LSF) and detect any extrahepatic deposition of activity. Moreover, 99mTc-MAA can also 
be used to predict the intrahepatic distribution of 90Y-microspheres and subsequently 
prescribe on an individualized treatment planning including a dosimetry step. Dosimetry 
can be used to optimize the tumor response and treatment efficacy with acceptable 
toxicity preventing complications by administration the highest possible activity to the 
tumor while maintaining low radiation dose to the sensitive and other healthy tissues 8–
11. 
1.2. Dissertation Aim 
Yttrium-90 radioembolization is a well-established therapy for the treatment of the liver 
diseases and also of metastatic liver deposits from other malignancies. The first aim 
this work was to make an evaluation be about 90Y-microspheres techniques and 
challenges facing it in terms of the dosimetry with focus on the Partition Method. In 
addition, in radionuclide therapy it is necessary to measure the distribution of the 
radiopharmaceutical in vivo. Measurements are usually performed by SPECT imaging. 
Thus, the second aim was to investigate the quality of Bremsstrahlung SPECT imaging 
using different reconstruction methods.   
1.3. Dissertation Structure 
This thesis is comprised of a background chapter and a series of chapters describing 
the findings and outcomes of this research.  
The second chapter presents general concepts of Nuclear Medicine that will be needed 
throughout this work. Chapter 2 includes the physics behind the Nuclear Medicine, the 
components and operation of a gamma camera as well as the development of SPECT 
reconstruction methods. And still the concepts and the current practice of nuclide 
therapy and the fundaments of the internal radionuclide radiation. 
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The third chapter presents the methodology of 90Y-microspheres radioembolization 
including treatment planning, activity and dose calculation and therapy. 
In chapter 4 is clarified the methodology used in this work with a pre-therapy and post-
therapy evaluation.  
Chapter 5 summarizes the results obtained as well as discussion of one of them. 
The last chapter presents the conclusions and discusses the future work. 
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2. Nuclear Medicine Fundamentals  
Nuclear medicine is a medical specialty that involves the administration of radioactive 
tracers (radiopharmaceuticals) that are used to diagnostic information and treat 
diseases in a safe and painless way. The radiopharmaceutical has a radionuclide 
labeled with a pharmaceutical and the mode of tracer administration will depend on the 
disease process that will to be implemented. For most diagnostic studies in nuclear 
medicine, the radioactive tracer is administered to a patient by intravenous injection. 
However, the radiopharmaceutical may also be administered by inhalation, by oral 
ingestion, or by direct injection into an organ 12. 
The type of radiation used is strongly linked with the purpose of the 
radiopharmaceutical. For diagnosis, the pharmaceutical is labeled with a gamma-ray-
emitting radionuclide or positron-emitting radionuclide. In therapy the radionuclide 
ideally has a pure negative beta-emitting or an alpha-emitting radionuclide. When the 
radionuclide decays, gamma-rays or high-energy photons are also emitted. Although 
some radiation interacts with body tissues by scatter and attenuation, a significant 
number can exit the body. The radiation that escapes can be externally detected by a 
sensitive gamma camera, and can be used to form an image of the distribution of the 
radiopharmaceutical in the body. The image of gamma-ray emission is performed with 
a single photon imaging (Planar imaging or SPECT with Anger camera) and the 
positron imaging (PET) is used when there is a positron emission. 
This work focuses on a particular therapeutic use of radionuclides in modern medicine. 
Before discussing about radionuclide therapy, a brief introduction on important 
concepts will be presented. 
2.1. Quantitative Imaging 
Radionuclide therapy is gradually becoming more important as a therapy option in 
various diseases or as adjunct to external beam radiotherapy and chemotherapy 13. 
Nuclear medicine imaging plays an important role in this process, before, during and 
after the therapy. Prior to the therapy, imaging can be used to predict dose to the tumor 
and surrounding organs, using a surrogate radiopharmaceutical. During treatment can 
be used for delivery control and dose assessment. After therapy it is important to follow 
the patient‘s response 14. 
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Nuclear medical imaging is based on detection of radiation distribution emitted from the 
body after administering a radiopharmaceutical. Thus, radionuclides that emit photons 
with appropriate energy (typically in the 60 to 600 keV range) for imaging during decay, 
the activity distribution in vivo can be estimated by imaging these photons outside the 
body using a scintillation gamma-camera. At the same time, the energy should not be 
so high that it cannot be collimated or detected efficiently. Gamma-emission imaging 
may be subdivided into categories, planar scintigraphy and emission tomography in the 
form of single photon emission computed tomography (SPECT) 15. 
2.1.1. Radioactive decay 
Radiological physics began with the discovery of x-rays by Wilhelm Rontgen, of natural 
radioactivity by Henri Becquerel, and of Polonium and Radium by the Curies in the 
1890s. The introduction of artificial radioactivity by I. Curie and Joliot prompted the 
invention of cyclotrons and reactors in which many radionuclides are now produced 
with different physical properties 16. 
Radioactive decay is a spontaneous process in which an unstable nucleus (parent) 
transforms into a more stable configuration (daughter) through expulsion of energetic 
particles. In many cases, the daughter is also radioactive and undergoes further 
radioactive decay. This process results in the conversion of mass into energy and the 
total energy (mass, quantum and kinetic) of photons and other particles released by the 
disintegration process is equal to the net decrease in the rest mass of the neutral atom. 
Total energy, momentum, and electric charge are each conserved in the process 17. 
Each radionuclide has a set of characteristic properties that include the mode of 
radioactive decay and type of emissions. The radioactive nuclei, X, disintegration is 
characterized by changes in the atomic number, Z (number of protons) and mass 
number, A (number of nucleons) when decays into a daughter, Y (Table 1). The main 
disintegration processes are alpha decay ( ), electron decay ( -), positron decay ( +), 
electron capture and gamma decay ( ). Several others processes can be also involved 
18. 
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Table 1 - Variation of atomic number (Z) and number of nucleons (A) in decay process.  
 ∆Z ∆A 
 -particle - 2 -4 
 - -particle +1 0 
 +-particle -1 0 
 -ray 0 0 
 
ALPHA DISINTEGRATION 
The α-decay occurs mainly in heavy nuclei such as uranium, plutonium and so forth. 
The α-particles consist in helium ions with two protons and two neutrons. The standard 
notation of the decay by an α-particle emission is represented as: 
  
  
             
→           
         
 
     Equation 1  
After decay, the mass number of the nucleus is reduced by 4 and the mass number by 
2, resulting in a transformation of elements. The kinetic energy of the α-particle is, in 
general, between 4 and 8 MeV. Despite the high-energy of the  -particles, they present 
several difficulties in diagnostic medical imaging, because the range is very short and 
cannot even penetrate the outer, dead layer of skin, Bremsstrahlung x-ray is also a 
major problem. However, α-particles have an increase medical interest for radiation 
therapy (e.g. Radium-223) 12,16. 
BETA DISINTEGRATION 
Beta decay 
When a radionuclide is neutron rich, it tends to emit an electron ( --particle), leaving 
the nucleus with one less neutron and one more proton. Schematically, the process is:  
          ̅    Equation 2  
The  --particle and the antineutrino ( ̅) are created at the moment of nuclear decay. 
The antineutrinos have no electric charge or mass, they do not interact with matter and 
therefore are essentially undetectable, unless in rather sophisticated experiments. In 
the  --decay, a neutron is converted to a proton, thus the atomic number Z is increased 
by 1. The atomic mass-energy balance equation is: 
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→            
      ̅                  Equation 3  
Mass number, A, does not change, this because the total number of nucleons (protons 
+ neutrons) remains constant, so that the parent and daughter are isobars.  
The energy released in the negative  --decay, this is, the difference of energy between 
parent and daughter nuclides is called the transition energy (    ). The      is the 
maximum possible  --particle energy, may be also shared with antineutrino. This result 
in a spectrum of energy as showed in Figure 1. 
 
Figure 1 - Shape of typical energy spectrum for  -particles (adapted from Podgorsak, 2010).  
Pure beta-rays can penetrate only relative small thicknesses travelling a short distance 
inside the tissue. Thus they are not useful for diagnostic imaging, because it is 
impossible to detect  -particles coming from a patient with a detector. Bremsstrahlung 
radiation is used, with poor image quality results. Nevertheless, a pure beta-emitter can 
be used in radionuclide therapy, as will be seen in section 2.2. In some cases, the 
beta-emitter radionuclides also emit gamma-rays. As mentioned, the high-energy of  --
particles can emit Bremsstrahlung x-ray. This can be the only radiation that is used for 
measurement in vivo 12,16,17.  
Bremsstrahlung is the German term for ―braking radiation‖. In the Bremsstrahlung 
process, a charged particle ( ) travelling in a material is slowed when it is deflected by 
another charged particle. As a high speed electron passes near atomic nucleus, its 
path of travel will be changed somewhat in the direction of the nucleus and, 
subsequently slow down and loses energy. In these cases, the energy lost is released 
in the form of electromagnetic radiation, called Bremsstrahlung.  
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Positron decay 
In the other hand, when the radionuclide has an excess of protons in the nucleus 
usually occurs a positron emission ( +-particle) accompanied by the emission of a 
neutrino. A positron is the antiparticle of an ordinary electron and its emission only 
occurs when the energy difference (transition energy) between the parent and daughter 
nuclides is greater than 1.02 MeV. In positron decay, essentially a proton is converted 
to a neutron reducing Z by one unit and leaving A unchanged: 
              Equation 4  
  
  
              
→            
           Equation 5  
After  +-emission, it loses its energy passing through matter. The range of  +-particles 
is short in matter, thus it interacts with a nearby electron and is annihilated, given rise 
to two photons of 0.511 MeV emitted in almost opposite directions. This process is 
called annihilation reaction and permits that the resulting photons to be useful in 
diagnostic imaging (PET) 12,16. 
ELECTRON CAPTURE 
Some nuclei undergo a radioactive decay by capturing an orbital electron, usually from 
K-shell because of its proximity. The captured electron is combined with a proton to 
form a neutron and eject a monoenergetic neutrino 12,17. This reaction is an alternative 
to  +-decay with same net effect, the Z decreases by 1, but A unchanged.  
               Equation 6  
  
  
              
→            
           Equation 7  
In this process, vacancy is created in the shell from which the electron is captured. 
When the vacancy is filled by the transition of an electron from the next upper shell, the 
remaining energy appears as characteristic x-ray and/or Auger electron emitted by the 
daughter nuclide 16.  
GAMMA-RAY EMISSION 
Gamma-ray decay occurs when a daughter nuclei in an excited state releases its 
excess energy by emission of electromagnetic radiation (photons) until it achieves a 
stable level. Transitions that result in gamma emission leave Z and A unchanged and 
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are called isomeric transition. These states may have lifetimes of fraction of 
picoseconds to many years. When isomeric states are long lifetime is known as 
metastable state, as in the case of the 99mTc 16.   
Metastable radionuclides are of great importance in nuclear medicine due to the fact 
that gamma-energy can be easily detected by external equipment. Although 
metastable nuclides always emit a certain number of conversion electrons, they do not 
contribute for the image because almost all are absorbed within the tissue 12. 
INTERNAL CONVERSION 
An alternative to the  -ray decay is the internal conversion (IC) process. This process 
can occur if excited nucleus transfers the excitation energy to an orbital electron, which 
is ejected instead of the  -ray. The ejected electron is called the conversion electron 
and carries the energy excess above the biding energy as kinetic energy. The orbital 
vacancy created by internal conversion consequently is filled by an electron from the 
next higher shell. And, such as in electron capture, characteristic x-ray and/or Auger 
electron are emitted 16. 
2.1.2. Radioactivity  
Radioactivity is characterized as spontaneously emission of radiation by an unstable 
nuclide. In general, there are two classifications of radioactivity: natural and artificial. 
However, the radioactive decay is a random process and is no way to predict with 
certainty the exact moment of its transformation into another stable nucleus. 
Mathematically, radioactive decay is described in terms of probability and average 
decay rates.  
The decay rate of a radionuclide is the number of disintegration per unit time, also 
referred as activity, denoted by A. In the others words, the activity is proportional to the 
total number of radioactive nuclei (dN) that decay in a period of time (dt) (Equation 8). 
The traditional unit of activity is the Curie (Ci), even though by System International (SI) 
the official unit of activity is the Becquerel (Bq), defined as one disintegration per 
second: 1 Bq = 1 s-1. The curie is thus defined as 1Ci = 3.7 x 1010Bq.       
   
  
  
        Equation 8 
The negative signal means that N decreases as the time t increases. The quantity   is 
the decay constant of the radionuclide and it has the dimensions of inverse time (s-1). 
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The decay constant is a characteristic value for each radionuclide and it represents a 
small fraction of the radioactive atoms that decays in a very short period of time 12,16,17.  
With the passage of the time, the number of atoms (N) in a sample decreases and 
consequently the activity also decreases. The factor that represents this decay is 
obtained by integration of Equation 8. The result is: 
       
   
     Equation 9  
       
       Equation 10  
where    is the number of atoms remaining after a time  ,    is the number of atoms at 
time     and      is the decay factor. The decay factor is an exponential function of 
time, thus both the number of radioactive atoms and activity remaining in the sample 
are decreasing continuously with time. A graph of either of these quantities is a curve 
that gradually approaches zero 19. 
 
Figure 2 - Exponential radioactivity decay, showing relative activity, A, as a function of time, t (adapted from 
Turner, 2007).  
Every nuclide is characterized by a half-life (    ), which is the expectative value of the 
time required for one-half of the initial radioactive atoms to disintegrate, and therefore 
the sample reduce to half of its existing activity. The decay constant and half-life of a 
radionuclide are related as 17: 
     
    
 
    Equation 11 
When considering the use of radioactive drugs for both diagnostic and therapeutic 
purposes another characteristic to be considered. This is because it disappears from 
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the body not only by radioactive decay but also by biological clearance. In this way, a 
new factor arises, the effective half-life (    ). It is defined as the period of time 
required to reduce the radioactivity level of an internal organ or of whole body to one 
half its initial value due to both decay and elimination. The effective half-life is then 
related by: 
 
    
  
 
  
   
 
  
     Equation 12 
The effective half-life takes into account not only the radioactive decay represented by 
physical half-life (  ) but also the elimination represented by biological half-life (  ). 
While the physical half-life is unaffected by anything that human can do to the 
radionuclide because is unique parameter for each radionuclide. The biological half-life 
represents the period of time required to reduce the amount of a radiopharmaceutical 
the body to one half its original value due solely to biological elimination 16. 
2.1.3. Gamma camera imaging 
Anger scintillation camera or gamma camera, as popularly called, is the most common 
imaging system used in Nuclear Medicine and radionuclide therapy 20. It is called in 
honor of Hal O. Anger, who invented it in the late 1950s 12. The equipment detects 
gamma photons emitted by radionuclides and forms planar or 2D projection images of 
the 3-D distributed radionuclides in vivo 15.  
Many sophisticated improvements have been made on the gamma cameras over the 
years. However, the basic principles of the operation have essentially remained the 
same. Figure 3 illustrates the basic principles of image formation with the gamma 
camera. The gamma camera converts photons, emitted from and transmitted through 
the patient, in electric signal if passing through a collimator and being detected by a 
scintillation detector 20. The major components are a collimator, a scintillation crystal, a 
light guide, an array of photomultipliers tubes (PMT), pulsed-height analyzer (PHA), an 
X-, Y-positioning circuit 12. The main components are described below.  
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Figure 3 - Basic components of a scintillation camera (adapted from Ljungberg et al, 2016). 
COLLIMATOR 
The collimator is the first component of the gamma camera after the photons leave the 
patient and is used to define the direction of the detected  -rays. The most common 
consist of a lead plate or a similar high atomic number substance and stopping power 
such as tungsten. They are designed in different sizes and shapes and contain a large 
array of holes (circular, triangular, square or more frequently hexagonal shaped) to 
view the area of interest. The purpose of the collimator is to permit that incident photos 
traveling along only certain directions, reaching the scintillation crystal and thereby 
providing a means to localize the site of the emitting sources. It is the image forming 
component of the Anger camera 15. 
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Image Image 
Collimators are primarily classified by the type of focusing, can be parallel-hole, 
pinhole, converging or diverging type. Pinhole collimator has a conic form with a single 
hole. Its main use is to give a significantly magnified image of a small organ such as 
the thyroid glands or heart. The organ must be located near a body surface so that the 
pinhole can be positioned close to it. There is a variation in resolution and sensitivity 
across an organ, and sensibility falls of quickly with increasing distance source-
aperture 12. Parallel-hole collimator is the most commonly collimator used in nuclear 
medicine procedures. This collimator is made with holes that are parallel to each other 
and perpendicular to the face of the collimator. The γ-rays image projected by this 
collimator has the same size as the source distribution onto scintillation crystal. 
Parallel-hole collimator are classified as low-energy, medium-energy or high-energy 
and high-resolution, all-purpose and high-sensibility. The characteristics of parallel-hole 
collimator such as septal thickness, septal length and size of collimator hole are 
chosen according to the energy of the radionuclide using for image 16. Converging 
collimators are made with tapered holes converging to a point in front of the collimator 
and are provide magnified images. This collimator is employed when the organ of 
interest is smaller than the size of the detector. Diverging collimator has holes that 
diverge from the detector face. In opposite to the converging collimator, images of 
organ larger than size of the detector are minified (Figure 4) 16.  
 
 
 
Figure 4 - Types of the gamma camera collimators: i) parallel-hole collimator, ii) converging collimator, iii) 
diverging collimator and iv) pinhole collimator (Adapted from Sharp et al, 2005) 
i) Parallel-hole 
iv) Pinhole iii) Diverging 
ii) Converging 
Image Image 
Focal Point 
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SCINTILLATION CRYSTAL 
The γ-rays that passed through the collimator interact with the detector. The detector 
used in gamma camera is a continuous scintillation crystal made from sodium iodine 
doped with a small amount of thallium, NaI(Tl) (Figure 5). The function of the NaI(Tl) 
crystal is to stop the gamma photons and convert these into visible light photons 
(scintillation) 15. The choice of the thickness of the crystal is a trade-off between 
detection efficiency and image quality. Because increasing the thickness of a detector 
increases the probability of complete observation of γ-rays and hence the sensibility, 
but resolution of the image of the area the interest deteriorates. Also, the probability of 
multiple Compton scattering also increases in thicker detectors 16.  
The amount of scintillation light produced following the interaction of a single gamma 
photon is proportional to the energy deposited by the incident photon and these optical 
photons are emitted isotropically from their point of creation. These photons deposit 
energy within the scintillation crystal by a photoelectric or a Compton scattering 
interaction. Therefore, the desired event is the photoelectric interaction where the 
entire energy of the photon is transferred to an electron and the photon ceases to exist. 
In a Compton scattering only a partial amount of the energy of the photon is transferred 
to the electron and the photon changes direction and loses energy. The visible light is 
then guided towards the photomultiplier tubes through the light guide increasing the 
light collection efficiency 12,15.  
 
 
Figure 5 - Schematic cross-section of a NaI(Tl) crystal assembly for a gamma camera (adapted from Cherry et 
al, 2012) 
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PHOTOMULTIPLIERS TUBES (PMTs) 
The photomultiplier tubes are fixed on the NaI(Tl) crystal with the photocathode facing 
the crystal by a special optical grease or connected to the crystal using light pipes. The 
PMTs are usually arranged in a close-packed array and are mounted in a hexagonal 
fashion to ensure that the smallest possible gaps are left between tubes 16. The visible 
light photons collected by a particular PMT are converted into electrons, multiplied and 
converted into an electrical signal 15. It amplifies the electronic signal (typically by a 
factor of 107) in order to generate a sufficiently large current to be received and 
processed by the subsequent electronics 21. The output signal from PMTs are fed into 
positioning logic circuits or software which is used to define the X, Y location of the 
point of interaction of the γ-rays in the detector 16.  
The amount of light photons detected by a PMT is inversely related to the lateral 
distance between the interaction site and the center of the PMT. The PMT closest to 
the point of interaction collect the largest number of light photons. Subsequently, it will 
have a largest output signal, with the amplitude of the signal output of the other PMT 
decreasing with increasing distance from the interaction point (Figure 6) 22.   
 
Figure 6 - Illustration of light photon sharing between PMTs. The PMT signal, S, is inversely related to the 
distance of the interaction site, D, from the center of the PMT (adapted from Cherry et al, 2012).  
ELECTRONIC INSTRUMENTATION  
The position information for an event on the crystal is used to form the 2D projection 
image and hence the final image depends of the distribution of signal amplitudes in the 
Collimator 
PMT array 
NaI(Tl) crystal  
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PMTs. The location of the gamma-ray interaction can be estimated by the calculation of 
centroid of the position-weighted PMT outputs, a process often referred to as Anger 
Logic or Anger Arithmetic 22.  
In analogue circuits the signals from PMTs are processed to give three signals required 
X, Y and Z. The X and Y provide spatial information the point of interaction of the γ-ray 
in the scintillation crystal by use an X-, Y-positioning circuit. The Z-signal is proportional 
to the total energy deposited in the crystal by a scintillation event produced simply by 
circuit the outputs from all the tubes. This electrical pulse is analyzed by a pulse-height 
analyzer (PHA) and is accepted if it falls within the range of selected energies 16,21. The 
spatial information is more complex to generate. All PM tubes are connected through 
resistors and the position is determined by splitting the signal from each PMT onto four 
output lines (X+, X-, Y+ and Y-). The output signal from each PMT is determined by the 
appropriate resistor values and then summed to form each of the X+, X−, Y+, and Y− 
signals individually 12.  
Also, these pulses can be stored in the computer. In modern camera systems, the 
output signal from each PMT is digitized and the event position is calculated in 
software. In digital cameras the analogue signal is required to be digitized. So, two 
general approaches are currently taken; the X, Y and Z signals are acquired in analog 
form and then digitized by analog-to-digital converters (ADC) to digital signals or the 
position signals and the total energy deposited being digitized before signals are 
computed. The position estimates are computed by combining only PMT with signals 
above a certain threshold. Therefore, with signal thresholding, only a small number of 
PMT surrounding the interaction location are used for position determination 16,22.  
PULSE-HEIGHT-ANALYZER (PHA) 
The summing circuit provides the energy signal (Z), which is proportional to the amount 
the light photons produced by a scintillation event in the crystal. After the Z pulses are 
formed by the summing circuit, each event is analyzed by pulse-height-analyzer (PHA). 
The PHA allows selecting only the Z signals where the gamma rays energy has a 
certain amplitude range of interest. This energy range is selected by use of appropriate 
peak and window setting, which is usually chosen according to the radionuclide being 
imaged 12,16.  
A typical energy spectrum includes several peaks. A typical example is the 99mTc 
spectrum with a gamma ray of 140 keV and typically a window equal to 20% centered 
symmetrically on the photopeak is employed. In Figure 7 is possible see the different 
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features of this spectrum. The photopeak is the peak that corresponds to interaction in 
which the total energy of the γ-ray (140 keV) is absorbed in the scintillation crystal, 
whereas other peaks in the energy spectrum represent some loss of energy from the 
detection process and therefore will be to the left of the photopeak. The Compton 
plateau results from the Compton scattering in the scintillator or detector and scattered 
photons that escape from the detector. In this situation only a fraction of its energy is 
registered by the detector with a peak from 0 to Emax. The Emax that corresponds to the 
Compton edge is the kinetic energy of those photons that are produced by the 180° 
Compton backscattering of the γ-ray photons in the detector. In addition, Compton 
scattering occurs not only in the detector but also outside of the detector. Some 
scattered photons, created inside the patient may lose only a small amount of energy. 
In such cases, a γ-ray can travel toward the detector, its energy may fall between the 
photopeak and the Compton edge 16. A characteristic x-ray is produced by 
photoelectric interaction of the γ-ray with the shielding or collimator. Because this 
interaction can cause injection of the k-shell electrons, followed by transition of 
electrons from the upper shells. The difference in binding energy between the levels 
appears as lead x-ray. The backscatter peak occurs when the gamma ray are 
scattered at 180º by Compton scattering in the source or surrounding structures and 
then absorbed in the crystal, appearing in the γ-ray spectrum 12. Iodine escape peak 
results from photoelectric interaction with iodine atoms of the NaI(Tl) crystal where 
usually occurs emission of characteristic K x-rays. This peak appears about 28 keV 
below the photopeak 12. 
 
 
Figure 7 - Energy spectrum of the 
99m
Tc showing the location of the Compton edge and effect of scatter. I) 
Spectrum obtained with a gamma camera of point source. II) Spectrum obtained with a gamma camera from 
patient (adapted from Prekeges, 2013). 
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2.1.3.1. Planar Imaging 
In planar imaging, the final images are a three-dimensional (3-D) distribution of the 
radioactivity as a two-dimensional (2D) projection. This results in an image with little 
depth information where structural information is obscured by superimposition of all 
photons emitted along projections lines. Thus, photons emitted also from overlying and 
underlying activity along the projection lines will contribute to the signal recorded in a 
particular pixel. This generally reduces the image contrast in the plane of interest. The 
problem can be minimized by obtaining multiple planar views (posterior, anterior, 
lateral, oblique) giving some information about the depth of a structure. For this reason, 
a 3-D imaging technique has been developed to tackle the problem directly 16,20.  
2.1.3.2. Single photon emission computed tomography 
SPECT imaging requires two fundamental components: a gamma camera and a 
means of performing image reconstruction 22. The tomographic mode of single photon 
imaging (SPECT) is based on detecting individual photons emitted isotropically by the 
radionuclide. The gamma camera rotates around the long axis of the patient to acquire 
multiple projection images at equal spaced angular intervals for collection of data over 
180º or 360º. The data are collected in the form of pulses at each angular position and 
normally stored in a 64 × 64 or 128 × 128 matrix in the computer.  As result provide a 
series of the static images at distinct depths of the organ of interest for later 
reconstruction 12,16.  
The idea behind tomography is to recreate the depth information along the projection 
line, in order overcome the problems of superimposition of radioactivity. Nevertheless, 
this can only be properly accomplished if certain requirements are followed: (i) a 
complete set of projections is acquired, (ii) the internal distribution is not spatially or 
temporally changing during the time that the projections are acquired, (iii) the detectors 
that acquire the projections have uniform detection sensitivity that remains constant 
throughout the acquisition, and (iv) the acquired projections have a common center and 
its accurate location is required for proper alignment of the projections during 
reconstruction 23.  
Older cameras were initially designed to rotate in circular orbits around the body. This 
causes loss of data and rapid degradation in spatial resolution with increasing distance 
of the object from the collimator. To circumvent this problem, many SPECT systems 
allow the detector head to trace out elliptical rather, permitting that the detector to pass 
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closer to the patient than would be the case with circular orbits, which can lead to 
significant improvements in spatial resolution (Figure 8) 12,16.  
  
Figure 8 - Illustration of circular (I) and contoured (II) orbits for SPECT imaging (adapted from Cherry et al, 
2012). 
In a reconstruction, it is assumed that the activity distribution remains stationary 
throughout the acquisition. However, it is important to note that the information 
collected by SPECT systems is not linearly related to the ray sums of activity in the 
patient because of tissue attenuation. This means that the difference in spatial 
distribution of counts in the acquired projection images limit the quality of reconstructed 
images. The advances in SPECT are directly knotted to improving the quality and 
accuracy of the acquired projections either through better instrumentation or 
reconstruction method 20,23.  
2.1.3.2.1. Reconstruction methods  
A basic problem in conventional radionuclide imaging is that the images obtained are 
2D projections of 3D source distributions. To obtain information along the depth of the 
organ of interest, tomographic images are used to calculate transaxial slices using 
mathematical algorithms 24. Reconstruction mathematical algorithms, such as filtered 
backprojection (FBP) method or an interactive reconstruction algorithm are two 
common methods of image reconstruction using the acquired data. In the past, the 
filtered backprojection method was the golden standard of reconstruction methods, but 
nowadays, due to the promise of better image quality in an acceptable time interval due 
to an increase in computer performance, iterative reconstruction methods are preferred 
I II 
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alternative methods for performing SPECT (and other tomographic image acquisitions) 
reconstruction 23. Both methods are described below. 
Before discussing reconstruction methods, it is necessary to introduce some general 
concepts. Assuming that the data is acquired by a dual-head gamma camera fitted with 
a conventional parallel-hole collimator with heads counted in opposition (i.e. 180º), the 
3D dataset of  -emitter distribution is obtained by pilling up many slices usually 
reconstructed independently. For this, the detector rotates around the organ of interest 
and allows one to observe the pattern of γ-emission in the field of view for many angles 
Figure 9 25. 
 
Figure 9 - Rotating the gamma camera around the object provides a set of 1-D projection profiles for a 2D 
object, which are used to calculate the 2D distribution of radioactivity in the object. ECT, emission computed 
tomography (adapted from Cherry et al, 2012). 
For the purpose of analyses, it is convenient to introduce a coordinate system (Figure 
10 - The (r,s) coordinate system is rotated by projection angle φ with respect to the 
(x,y) coordinate system of the object and is fixed with respect to the gamma camera 
(adapted from Cherry et al, 2012). that is stationary with respect to the gamma camera 
detector. Defining (r, s) as the estimated number of photons emitted at any point (x, y), 
of the transverse slice in the field of view. And If the camera is rotated by an angle   
with respect to the (x, y) coordinate system of the scanned object, the equations for 
transformation from (x, y) to (r, s) coordinates can be derived from the principle of 
similar triangles and are given by:  
Rotating gamma 
camera 
1-D projection 
profiles at 
different angles 
 
Reconstructed 
image of section 
through object  
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                  Equation 13 
                  Equation 14 
These equations can be used to determine how radioactivity at a location (x,y), for 
each detector angle φ, and for each location r on the detector. Because the collimator 
allows only photons whose direction is parallel to the axis of its holes to be potentially 
detected. 25.  
 
Figure 10 - The (r,s) coordinate system is rotated by projection angle φ with respect to the (x,y) coordinate 
system of the object and is fixed with respect to the gamma camera (adapted from Cherry et al, 2012). 
A common representation of the matrix p(r, φ) is generically known as a sinogram 
(Figure 11). A sinogram is a 2D image, in which the horizontal axis represents the 
count location on the detector, and the vertical axis corresponds to the angular position 
of the detector. The successive rows from top to bottom represent successive 
projection angles. The sinogram provides a convenient way to represent the full set of 
data acquired during a scan and can be useful for determining the causes of artifacts in 
SPECT image. For example, this should demonstrate the smooth progress of the 
camera head around the patient and any discontinuity indicates patient movement 12,25.  
p(r, φ) 
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Figure 11 - Sinogram. Each row of sinogram is projection of slice at given angular position of detector (adapted 
from Cherry et al, 2012). 
FILTERED BACKPROJECTION 
Filtered backprojection (FBP) is a modification of an older technique, called 
backprojection or simple backprojection. Simple backprojection is a common sense 
approach, but much unsophisticated. The principle of simple backprojection is 
illustrated in Figure 12 in which a point source object is acquired from different angles. 
An image of the original distribution is by ―backprojecting‖ each profile at the 
appropriate angle on to an image array in the computer. An approximation for the 
source distribution within the scanned slice is obtained when all projection profiles 
acquired are added together 12.  
 
Figure 12 - Basic principle of image reconstruction by the backprojection algorithm. (I) Projection profiles for a 
point source of radioactivity for different projection angles. (II) Backprojection of one intensity profile across 
the image at the angle corresponding to the profile. This is repeated for all projection profiles to build up the 
projected image (adapted from Cherry et al, 2012). 
φ 
r 
Point source 
 
Projection 
profiles 
Object   
Backprojection 
of profile at 0º 
across image 
matrix. 
2 angles 8 angles 256 angles 
Backprojection after  
I 
II 
FCUP 
Development of an advanced partition model dosimetry system for hepatic radioembolization 
using 
90
Y-microspheres 
23 
 
However, when the number of projections is small relative to the matrix size, there is a 
―star-pattern‖ artifact resulting from counts that inevitably are projected outside the true 
location of the object, causing a blurring final image 25. Mathematically, the relationship 
between the real image and the image reconstructed by simple backprojection is 
described as: 
  (   )    (   )   
 
 
    Equation 15 
This way, the blurring effect can be reduce by increasing the number of acquired 
projections and by decreasing the distance (r) from the object of interest 12. In addition, 
this problem can be minimized by filtering the profiles prior to backprojection and, the 
filtered projections are then backprojected to produce an image that is more 
representative of the original object 16. 
It is important to understand that nuclear medicine data is obtained in the spatial 
domain. And, the frequencies of an image are similar to the frequencies of a sound, 
where the data for each row and column of the acquisition matrix can be considered as 
composed of sinusoidal waver of varying amplitudes and frequencies. Thus, using the 
mathematical technique known as Fourier analysis, it is possible to describe images in 
terms of their spatial frequencies. The Fourier method of filtering the projection data in 
the Fourier domain is based on the initial transformation of these data from the spatial 
domain, represented by  (   ), to the frequency domain,  (     ),  which is denoted 
as 12,16,25: 
 (     )     (   )    Equation 16 
Finally, the operation of converting the Fourier transform (FT) of a function back into 
the original function is called an inverse FT and is expressed as 12: 
   [ (     )]   (   )   Equation 17  
In this method, filters are used to eliminate the blurring function 1/r that arises from 
simple backprojection of the projection data. The idea is apply a Fourier filter applied in 
 -space before perform the inverse FT. In nuclear medicine, a number of Fourier filters 
have been designed and used in the reconstruction of image. In common, it have the 
called Nyquist frequency, that gives an upper limit to the number of frequencies 
necessary to describe the sine or cosine curves representing an image projection 16. 
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A well-known filter is the ramp filter (Figure 13), which gives a weight proportional to its 
frequency to each of the components. This filter will enhance the higher spatial 
frequencies, the aim being to restore higher spatial frequencies lost by the back-
projection process. However, this can also be a problem, because the noise associated 
with high frequencies in the image is amplified. In addition, the ramp filter to suppress 
low spatial frequencies that help to removes the blurring effect of simple backprojection 
12,16. 
 
Figure 13 - (I) Ramp filter in the spatial-frequency (k-space) domain. (II) Illustration of the steps in filtered 
backprojection. The 1-D Fourier transforms of projection profiles recorded at different projection angles are 
multiplied by the ramp filter. After taking the inverse Fourier transform of the filtered transforms, the filtered 
profiles are backprojected across the image, as in simple backprojection (adapted from Cherry et al, 2012). 
To eliminate the high-frequency noise, a window is applied to the ramp filter. The effect 
of a decreasing window at higher frequencies is to eliminate the noise associated with 
them. The frequency above which the noise is eliminated is called the cut-off 
frequency. The typical cut-off frequencies vary from 0.2 to 1.0 times the Nyquist 
frequency, being that the Nyquist frequency is the highest cut-off frequency. The choice 
this frequency should be a compromise between noise reduction and image details 
preserved, because with a very high cut-off value, image detail may be lost 16.  
To minimize these effects on signal-to-noise ratio (SNR) and artifacts at sharp edges a 
variety of reconstruction filters have been developed, each with its own theoretical 
rationale. Hann, Hamming, Parzen, and Shepp–Logan filters are all low-pass filters 
because they preserve low-frequency structures, while eliminating high frequency 
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noise. Butterworth filter is an important low-pass filter that is most commonly used in 
nuclear medicine. This filter has two parameters: the cut-off frequency (fc) and the 
order (n) 16. The cut-off frequency defines the frequency at which the filter attenuates 
the amplitude, which for the Butterworth filter is 0.71. One has to be aware of the fact 
that, by limiting the frequency content of an image, not only is noise is reduced, but 
also useful information may be lost. The order of the filter allows changing the slope of 
the filter function that is determines how rapidly the attenuation of amplitudes occurs 
with increasing frequencies. Thus, the higher the order, the greater the slope. No filter 
is perfect and, therefore, the design, acceptance, and implementation of a filter are 
normally done by trial and error with the ultimate result of clinical utility 26. 
ITERATIVE RECONSTRUCTION 
FBP has some limitations due to the presence of streak artifacts that are particularly 
prominent near hot structures and the noise enhancement that is inherent in the 
reconstruction. An alternative to FBP is the use of iterative reconstruction techniques, 
which can more readily incorporate more complex models of the underlying physics 
and also can better accommodate assumptions regarding the statistical variability of 
acquired data. As this method is more complex, is also computationally more intensive 
than FBP.  
 
 
 
 
 
 
 
 
 
Figure 14 - Schematic of general iterative reconstruction algorithm (adapted from Cherry et al, 2012). 
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The general concepts of iterative reconstruction are outlined in Figure 14. The basic 
principle of the iterative reconstruction is to find a solution by successive estimates until 
a satisfactory agreement is achieved 12. This method tries to determine the ―best‖ 
estimate of the distribution of activity comparing the estimated image with the 
measured image. The iterative algorithm involves a feedback process that permits 
sequential adjustment of the estimated reconstruction so as to improve its 
correspondence with the measured projections. In practice, a first estimate of the 
internal source distribution is made and the computer algorithm calculates a projection 
image (sinogram), using a process called forward projection. This image is then 
compared with a measured projection to determine where in the modeled image 
differences occur. As the first result will differ from the actual measured projections, 
unless the initial guess happens to coincide exactly with the actual object. However, 
the difference between the estimated and actual projections can be used to adjust the 
estimated image to achieve closer agreement. This proceeds as the first with the 
forward projection so as to re-estimate the projections that would derive from this 
updated object. The successive adjusts led that the estimated image progressively 
converges toward the true image 12,27.  
Most reconstructions in nuclear medicine use the statistical iterative reconstruction 
methods such as the Maximum Likelihood Expectation Maximization (MLEM) method 
and Ordered Subsets Expectation Maximization (OSEM) method. The MLEM method 
basically consists in obtaining the parameters that maximize the likelihood of the 
statistical model given any outcome. This method requires much iteration to achieve a 
satisfactory agreement between the estimated and measured images and, between 
iteration updates the image, demanding a lengthy computation time. A version of the 
MLEM algorithm is the OSEM, which, due to the improved calculation efficiency, has 
made the iterative reconstruction methods practical for clinically routine studies. With 
OSEM, the projection data is grouped into an ordered sequence of subsets separated 
by some fixed angle. For each subset, MLEM is applied and the expected projection 
values are computed from the estimation of the pixel values in all projections in the 
subset and compared with the measured image. However, in OSEM the estimated 
image is updated, that is, the first full iteration is complete, after only a subset of 
uniformly-distributed angles has been processed. This means that, in each sub-
iteration, instead of computing all projection data, only the projection data in subset are 
computed in the forward projection. The OSEM method considerably shorten the 
computing time needed for reconstruction, thus, the convergence rate is reached much 
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faster and with an accelerating factor, relative to the MLEM algorithm, roughly equal to 
the number of subsets 16,20,25.  
2.2. Radionuclide Therapy  
The nuclear medicine therapy is required to be highly specific and targeted, since it 
involves administration of unsealed sources of radioactivity. The concept of targeted 
radionuclide therapy (TRT) is like chemotherapy as it is a systemic treatment, bring 
about by injection radioactive substances into the blood stream 28. The method of TRT 
uses radionuclide pharmaceuticals that allow deliver therapeutic doses of radiation 
directly to the targeted site of disease with potentially less toxicity from exposure of 
normal tissues. One of the most appealing benefits of TRT is the possibility for 
personalized medical care, optimized for patient and disease characteristics patient 
and disease characteristics 29,30. However, the efficiency of the TRT relies on the 
delivery of the radiopharmaceutical to the intended tumor site. When the 
radiopharmaceutical is effectively delivered, it is retained on those tissues and decays 
for a certain period of time, emitting a prolonged radiation dose to kill cancer cells and 
minimize tumors by damaging the cells‘ DNA, thereby stopping these cells from 
continuing to grow and divide 31.  
The biological effect in the target radionuclide therapy depends of energy absorbed 
from the radiation emitted by the radionuclide. In nuclear medicine imaging, the 
radionuclides used emit gamma rays, which can penetrate profoundly into the body. 
The radionuclides used for target radionuclide therapy should emit radiation with a 
relatively short path length to must irradiate tissue volumes with multicellular, cellular 
and subcellular dimensions. There are three types of particles radiation possible for 
radionuclide therapy that is beta ( ) particles, alpha (α) particles and Auger electrons.    
2.2.1. Radionuclides Selection 
Such as in nuclear medicine imaging, in which the radionuclides have some specific 
characteristics, also the radionuclides for targeted therapy must comply with several 
requirements. The selection of the therapeutic radionuclide for clinical usage depends 
on several factors such as type of emissions, energy of the radiation, half-life, method 
of production, radionuclide purity and cost 28,31–33.   
Physical and effective half-life of the radioisotope should be paired to the drug half-life 
in the body is an important factor for the therapy planning. An optimal half-life for 
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isotopes used for radionuclide therapy ranges from six hours to seven days. 
Radioisotopes with very short half-life limits the preparation of pharmaceutical flexibility, 
its transport and delivery storage and patient transportation, while radionuclides with 
longer half-life promote an increase to absorbed dose not only in the target tissue, but 
also in the surrounding areas. Therefore, for an efficient radiation delivery, a balanced 
optimal biological and physical half-life should be chosen, so that the  resulting 
effective half-life be an appropriate time for maximum therapeutic effect and minimal 
radiation risks and toxicity for the health cells 31–33.  
For therapeutic purposes, the radioactive decay of radionuclides is expected to cause 
significant damage to cancer cells and the action is determined by the form of ionizing 
radiation emitted by the radionuclide. This damage is mediated by the linear energy 
transfer (LET), which is defined as the rate of energy loss by the radiation (dEL) in the 
medium per unit distance (dl):  
    = 
   
  
     Equation 18  
LET is an important parameter for understanding energy deposition effects on living 
cells 34. Potentially, radionuclides that emit α,   particles and Auger electron are 
assumed to display the highest therapeutic efficiency, because these types of 
radiations allow very high ionization in extremely short path length. Seeing that, they 
are fully deposited within a small range of tissue, usually a few millimeters 31,33.  
The specifications of the radionuclide chosen for a give application will depend on 
many others factors that include the type of disease to be treated, the accessibility of 
the disease site, the target and the biochemical mechanism addressed, 
pharmacokinetic of the radiopharmaceutical as well as the availability and cost of the 
radionuclide 35.   
The Auger electrons is the low-energy electrons (<1 keV) that result of the internal 
emitters that undergo radioactive decay by electron capture (EC) and/or internal 
conversion (IC). The very low energies of Auger electrons have two important 
consequences that become less clinically efficient. First, they emit the particles 
dispersed form and in a short range (<1 nm to a few μm), requiring their close proximity 
to the radiosensitive target (DNA) for radiotherapeutic effectiveness. Second, the linear 
energy transfer for Auger electrons varies between 4 – 26 keV/μm, that is, multiple 
ionizations occur around of the decay site. These characteristics make the 
radionuclides that emit Auger electrons more suitable for the treatment of small groups 
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of cancer cells or small tumor deposits. It is worth that the radionuclides producing 
Auger effects on electron capture are often used for diagnostic purposes, as is the 
case of 99mTc  28,33,36–38. The  -particles, which are 4He nuclei, have high linear energy 
transfer values (80 – 100 keV/µm), the path length is in the range of 50-100 µm for 
mean energies of around 5 – 8 MeV. These properties render  -emitting isotopes 
highly efficient for therapeutic purpose due to it is capability to deliver a higher radiation 
dose at cellular level. Because of the high LET and short path length the induction of 
irreparable damage in DNA is very probable, since the ionizing events occur in the 
range of about 2 nm, close to the diameter of DNA double helix. In α therapy, high 
degree of accuracy is required to deliver the radiation to the target cells without 
targeting healthy cells, for once the double-stranded DNA molecules break, there is 
very little chance for repair 28,31,33,38. In current clinical treatment the  -emitting isotopes 
are most widely used for TRT at present.  -particles are negatively charged electrons 
that are emitted from nucleus of decaying radioactive atom (1 electron/decay). After 
emission, the daughter nucleus has 1 more proton and 1 less neutron. The range of  -
particles in tissue is 0.05 to 12.0 mm and has wide energies range (50 – 2300 keV). 
Due to the range of these particles most of their energy is dissipated within an organ, 
being is indicated for the treatment of larger tumors. In addition, the LET of these 
energetic particles is low (0.2 – 2.0 keV/ µm), which causes less damaging than high 
LET radiation, as is the case of the  -particles and Auger electrons (Figure 15) 31,37,38. 
An important consequence of the relative long range of emitted electrons is the 
production of cross-fire, where the   electrons energy is deposited in neighboring, non-
target cells, is due to the larger range of  -particles in the soft tissue. The main 
advantage of cross-fire is that negates the necessity of the radiotherapeutic agent to 
target every cell within of tumor; but it has the disadvantage of delivering a significant 
dose to adjacent normal tissue that can be destroyed 28,37,38.  
Some therapeutic  -emitting nuclides produce Bremsstrahlung radiation and could 
have different energies and intensities. This associated gamma ( )-radiation could be 
advantageous if the energy and intensity are within the diagnostic range (100 – 200 
keV) because is possible following the pharmacokinetics as well as in vivo localization 
of the radiopharmaceutics as a function of time by using gamma scintigraphy methods. 
The  -radiation contributes very little to therapeutic effectiveness 38. 
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.  
Figure 15 - Local density of ionization produce along track of energetic   -particles, Auger electrons and α-
particles 
38
.  
In some cases, mixed emitters are used to allow both imaging and therapy with the 
same radionuclide, as is the case of 131I, which emits the mixed beta/gamma particles. 
Moreover, for each type of particles, there are multiple radionuclides with a variety of 
tissue ranges, half-lives and chemistries, offering the attractive possibility of tailor-
making the properties of a target radionuclide therapeutic to the needs of an individual 
patient 39.  
2.2.2. Radionuclide Application 
For many decades, radionuclide therapy was one of the most intensively developing 
directions of nuclear medicine. The target radionuclide therapy is based on the use of 
molecular carriers of radionuclides with high affinity to tumor cells and, the choice of 
radionuclide depends on the tumor characteristics. The development of radionuclides 
such as iodine-131 (131I), phosphorous-32 (32P), strontium-89 (89Sr), lutetium-177 
(177Lu), radium-223 (223Ra) and yttrium-90 (90Y) emit charges particles with therapeutic 
effects and also allow in vivo imaging. These radionuclides in therapy have been used 
successfully for the treatment of metastatic bone pain, neuroendocrine and other 
benign or malignant disease 30,31,33,37,40.  
Radioactive iodine labeled with sodium iodine (131I-NaI), in capsule or liquid form, is 
commonly used in different thyroid disorders such as Graves‘ disease, 
hyperthyroidism, or even, to reduce the thyroid volume 30,33,37,41. 131I has also been used 
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for treatment of patients with differentiated thyroid cancer and generally done post-
surgical removal of the solid tumor. The radioiodine ablation it seeks to eliminate 
thyroid remnants and consequently evaluate the differentiated thyroid cancer 
persistence or recurrence through of diagnostic whole-body scintigraphy 35,42. With a 
physical half-life of 8.02 days and with the maximum and average beta particles energy 
of 0.61 keV and 0.192 keV, respectively, the 131I has suitable characteristics for 
therapy. However, the abundance of high energy gamma photon (364 keV – 81% and 
636 keV – 7.27%) present in the 131I deposits unnecessary dose to surrounding tissues 
35,41. 
Others pharmaceuticals for TRT with 131I component are introduced in clinical practice. 
131I-tositumomabar (Bexxar®) was used to treat certain types of non-Hodgkin‘s 
lymphoma. Bexxar® was approved by the USA‘s Food and Drug Administration (FDA) 
in 2003. However, in 2014 was taken out of production because of commercial reasons 
30,31,33. Meta-iodobenzylguanidine labeled with 131I (131I-mIBG) have indications to be 
used in treatments such as pheochromocytoma, paraganglioma, neuroblastoma, 
carcinoid, medullary thyroid carcinoma. The therapy is administered for intravenous 
infusion 33,43,44. 
Bone pain is caused by skeletal metastases associated with prostate and breast 
cancer, in about 80% of the cases. Radionuclide therapy has played an important role 
in palliation of painful bone metastases that reduces the patient quality of life 33,45,46. 
There are a number of options of radionuclides, 89Sr chloride (Metastron®), 32P, 153Sm-
EDTMP (Quadramet®) and 186Re-HEDP. Strontium is chemically similar to calcium and 
hence mimics the metabolism of calcium and is associated with rapid washout form 
normal bone and prolonged retention in diseased bone 35,45,46. 32P as phosphoric acid 
was one of the earliest be used how therapeutic radiopharmaceutical for bone pain 
palliation. Like 89Sr (1.497 MeV), 32P (1.711 MeV) presents hard beta energy, which 
can induce bone marrow toxicity to the patients. Meanwhile, other isotopes with lower 
energy have been developed such as 153Sm-EDTMP. The beta energies of 153Sm (808 
keV – 17.5%, 705 keV – 49.6% and 635 keV – 32.2%) have the advantage over 89Sr 
due to low bone marrow involvement. However, the 153Sm is not a pure   emitter with a 
gamma abundance of about 35% (103 keV – 28.3% and 70 keV – 5.25%) capable of 
producing imaging of the distribution 32,35,45–47. The first approved α emitting 
radiopharmaceutical was 223Ra dichloride (Xofigo®; Bayer Healthcare Pharmaceutical). 
The 223Ra selectively targets bone metastases with α particles and the results are 
promising increasing overall survival 30,48. 
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32P therapy has been an accepted treatment for myeloproliferative disease for more 
than 30 years. The therapy is proposed for a group of elderly patients with 
polycythaemia vera characterized by an absolute increase in red blood cell mass, and 
essential thrombocythaemia characterized by unremitting thrombocyte elevation  
32,35,49. 
177Lu-labeled radiopharmaceuticals have several therapeutic applications. 177Lu is a 
medium-energy  -emitter (0.5 MeV) with low abundance of γ-rays (113 keV – 3% and 
208 keV – 11%) offering the possibility to perform diagnostic imaging. The lower tissue 
penetration range of 177Lu (maximum range of 2.1 mm) shows to be advantageous for 
the treatment of small tumors 32,33,40,50. In the literature has been reported the success 
employed in labeled somatostatin analogues with 177Lu offering an opportunity to treat 
receptor-positive tumors 45,46. At present, are available [177Lu-DOTA]-Phe1-Tyr3-
octretide (177Lu-DOTATOC), [177Lu-DOTA]-Tyr3-octreotate (177Lu-DOTATATE), among 
others 35,46,50–53. Monoclonal antibodies have also been successfully radiolabeling with 
it, for example the CC49, which reacts with a wide range of human carcinomas 35.  
90Y is an attractive choice for radionuclide therapy and there are several well 
established radiopharmaceuticals that incorporate it. The high energy  -emitter and 
longer path lengths of 90Y may be preferable for treating larger tumors 33,50. Such as 
177Lu, also 90Y labeled with DOTA conjugated somatostatin analogues (e.g. [90Y-
DOTA]-Phe1-Tyr3-octreatide and [90Y-DOTA]-lanreotide) has been used for peptide 
therapy in neuroendocrine tumors (NET) patients 31,33,35,40,46,50. In 2002, the USA‘s Food 
and Drug Administration (FDA) approved the first pharmaceutical for 
radioimmunotherapy (RIT), Zevalin®. Zevalin is based on a monoclonal antibody 
targeting the CD20 antigen, ibritumomab, conjugated with 90Y by the metal chelator 
tiuxetan (90Y-ibritumomab tiuxetan). CD20 is one of many antibodies expressed on the 
mature B-cells. 90Y-ibritumomab tiuxetan has been used as a radioimmunotherapeutic 
agent for the therapy of follicular B-cell non-Hodgkin‘s lymphoma 31,33,40,54. The FDA 
requires that be performed a pre-therapeutic whole-body scan using 111In- ibritumomab 
tiuxetan to confirm the biodistribution of 90Y-ibritumomab tiuxetan 54.  
Liver is a common site for metastasis from many primary neoplasms. For example, 
since almost the whole venous blood of the gastrointestinal tract first flows through the 
liver can be frequently found colon cancer metastasis. But, primary liver cancer 
(hepatocellular carcinoma or cholangiocarcinoma) also are recurrent. A treatment 
option is the selective internal radiation therapy (SIRT). This treatment is in particular 
related to patients whose liver tumors are not resectable or do not adequately 
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responding to chemotherapy. SIRT is based on the administration of 90Y-resin (Sir-
Spheres®, Sirtex Medical, Lane Cove, Australia) or 90Y-glass (TheraSphere®, MDS 
Nordion, Kanata, ON, Canada) microspheres directly into the tumor tissue of the liver 
by means of femoral or radial catheter application. 90Y-microspheres are delivered in 
aqueous solution and the radioactive contamination is a concern, therefore be 
considered as open sources 40,55,56. As in Zevalin treatment, a pretherapy evaluation 
must be carried out, in this case, with 99mTc labeled albumin macroaggregate (99mTc-
MAA) 56. 
Several pharmaceuticals for TRT are available for clinical practice. Table 2 shows a 
summary of the physical characteristics, and clinical indication of the commonly 
available therapeutic radionuclides 31,33,35,45.  
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 Table 2 - Radionuclides useful in targeted radionuclide therapy. 
Nuclide 
Physical 
Half-life (σ1/2) 
Mode 
decay 
Maximum 
E (MeV) 
Principal E  
(MeV) 
Maximum 
range in 
tissue (mm) 
Radiopharmaceutical Disease 
32P 14.3 days  
-
 1.71 - 7.9 
32
P phosponate Polycythemia vera, essential thrombocythaemia 
89Sr 50.5 days  - 1.49 - 7.0 
89
Sr chloride 
(Metastron®) 
Painful bone metastasis 
90Y 64.1 hours  - 2.28 - 11.3 
90
Y-DOTATOC Neuroendocrine tumors 
90
Y-ibritumomab tiuxetan 
(Zevalin®) 
Non-Hodgkin‘s lymphoma 
90
Y-microspheres Liver Metastasis; hepatocellular carcinoma 
131I 8.1 days  -,   0.61 0.364 2.3 
131
I sodium iodine Differentiated thyroid carcinoma 
131
I-tositumomab 
(Bexxar
®
) 
Non-Hodgkin‘s lymphoma 
131
I-MIBG 
Neuroblastoma; Pheochromacytoma; Carcinoid; 
Paraganglioma; Medullary thyroid carcinoma 
153Sm 46.3 hours  -,   0.81 0.103 3.0 
153
Sm-EDTMP 
(Quadramet®) 
Bone pain palliation 
177Lu 6.73 days  -,   0.5 0.113 and 0.208 1.8 
177
Lu-DOTATOC 
Neuroendocrine tumors 
177
Lu-DOTATATE 
186Re 3.8 days EC,  - 1.08 0.137 4.8 186Re-HEDP Painful bone metastasis 
188Re 17 hours  -,   2.12 0.155 10.4 188Re-HEDP Painful bone metastasis 
223Ra 11.44 days  ,  ,    5.98 0.154 < 10  
223
Ra dichloride 
(Xofigo
®
) 
Bone metastasis 
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2.3. Characteristics of 90Y emission 
Yttrium-90 is an important radioisotope, essentially  -particles emitter with a physical 
half-life of 2.67 days (64.2 h), and averages electron energy of 0.935 MeV and a 
maximum energy of 2.3 MeV. The average penetration range in soft tissue is 2.5 mm 
and maximum range is 11 mm, and 90% of the emitted energy is absorbed within a 
sphere with a radius of 5.3 mm 57–59. The convenient physical characteristics as well as 
its availability from a 90Sr/90Y generator make it a very attractive choice for developing 
agents for radionuclide therapy. Currently, has found commercial application in 90Y-
microspheres for hepatic radioembolization 29,56,60.  
The isotope 90Y can the produce by the irradiation of 89Y in a reactor by the 89Y(n, )90Y 
reaction and through the decay of 90Sr. The feasibility of production of 90Y from a 
90Sr/90Y generator is more favorable, because makes this radionuclide should be 
readily available in sufficient quantities.  The decay scheme of 90Sr to 90Y is show in 
Figure 16. The 90Sr decays completely by  – decay with no accompanied γ-radiation 
(σ1/2 = 28.78 years, Eβ = 0.546 MeV). The daughters 
90Y also decay by  – decay and 
without accompanied  -emission 28,35. 
 
Figure 16 - Decay scheme for 
90
Sr/
90
Y 
35
. 
A characteristic of 90Y, suitable for therapy, to be considered is that 90Y decays over 
99.99 % of the time via  – decay to the ground state of 90Zr. Although 90Y decay does 
not result in γ-emissions, it does produce secondary photons – Bremsstrahlung 
photons 56,58,61. The Bremsstrahlung photons are broad-spectrum secondary  -ray 
emissions that result of the interaction of high energy  -particles emitted by 90Y with 
tissue 62. The quantitative the imaging of 90Y Bremsstrahlung photons can be obtained 
using a dual-head gamma camera equipped with medium-energy collimators through 
static planar imaging and/or a single photon emission computed tomography (SPECT) 
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image. Conventional Bremsstrahlung imaging is used in the detection of suspected 
extra hepatic deposition and to verify the 90Y-microspheres biodistribution for target 
radionuclide therapy dosimetry application 54,57,58,60–62. In the absence of a photopeak, 
SPECT imaging of 90Y is dependent on the continuous and broad spectrum of energy 
distribution of Bremsstrahlung photons54. In contrast to imaging conventional gamma 
photons emitters, where the acquisition energy windows are usually placed around 
photopeaks, the same does not happen with 90Y energy spectrum. Due to the 
continuous nature of the Bremsstrahlung photon energy spectrum there has great 
variation in the choice of the acquisition energy window being can result in a reduced 
image quality. This is because exist a substantial numbers of scattered photos in any 
energy window 29,61. In quantitative imaging and accuracy are important optimize the 
acquisition energy window as well as choose an appropriate reconstruction methods.  
2.4. Internal Radionuclide Radiation Dosimetry 
Radionuclide therapy aims to incorporate an unsealed radiation source in appropriately 
large amounts into target tissue, delivering a radiation dose sufficiently to produce a 
therapeutic effect, while maintaining possible side-effects to normal tissue at tolerable 
levels. Thus, a proper and accurate personalized dosimetry should be requirement for 
in vivo quantification of radiation distributions, as well as its re-distribution over time 
20,63. 
Internal radionuclide radiation dosimetry is useful for estimate the quantities and spatial 
and temporal distribution of radiation energy deposited in different tissue by 
radionuclides. In order to obtain patient-specific dosimetry, information about the time-
dependent characteristics of the radionuclide distribution and description of patient 
anatomy and body composition becomes imperative for the absorbed dose calculation 
and these are based on modeled biodistribution data and on quantitative imaging 
procedures 63,64. Measurements of patient anatomy as mass/volume of target organs 
are usually performed by computed tomography (CT) or magnetic resonance imaging 
6,65,66. With radionuclide and patient information established several methods have 
been developed for estimating radiation dose. A methodology widely used for internal 
dose calculation was developed by the Committee of the Society of Nuclear Medicine 
is the Medical Internal Radiation Dose (MIRD) formalism 64,67,68. In internal dosimetry 
and radiation protection the fundamental quantities that should be considered are: the 
absorbed dose ( ), which defines the mean energy absorbed per unit mass of any 
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material and expressed in Grays [1 Gy = J.kg-1]; the equivalent dose (  ) is defined as 
the product of the average absorbed dose and a dimensionless radiation weighting 
factor (  ) which is measured in Sieverts [Sv]; the effective dose ( ) is defined as the 
sum of the weighted equivalent doses over all tissues, multiplied by the appropriate 
tissue weighting factor (  ), and is express in [Sv] 
19,34,64.  
2.4.1. Medical Internal Radiation Dose  
In Nuclear Medicine the radiation dose received by the patient is received from 
radioactive materials within the body, they are referred to as internal dose and cannot 
be directly measured as happen with distinct radiation dose received from external 
sources such as an  -ray machine 6. The MIRD formalism is used to calculate the 
absorbed radiation dose from internally deposited radionuclides. Absorbed dose is a 
quantity that usually is estimated from localized distribution of administered 
radiopharmaceuticals, the radiation decay data of radionuclide and simulations of 
radiation transport in anthropomorphic models. The measurement of the absorbed 
dose in patient is established in this first approach becoming an important factor in 
assessing risk and therapeutic utility 69.  
The schema propose by the MIRD is based on the assumption of homogenous 
distribution of the activity throughout the mass of interest and all of the energy emitted 
is absorbed 6,58,70,71. The calculation involve the energy emitted per radioactive decay, 
the fraction of the emitted energy that is absorbed dose in various target organs, the 
masses of the organs and both the physical and biologic decay of the injected 
radionuclide. Absorbed dose rate ( ̇(     )) to target tissue    is given as:  
 ̇(    )    ̃(    )  (       )   Equation 19  
where  ̃(     ) is the cumulated activity of the radiopharmaceutical in source tissue    
and  (       ) is radionuclide specific quantity representing the absorbed dose rate to 
target tissue    at time   after administration per unit cumulated activity present in 
source tissue    
6,58,68,70–73. The cumulated activity is dependent on biological 
parameters because represents the total number of radioactive decays occurring within 
the source organ in which a radiopharmaceutical accumulates. The term  (       ) 
usually is referred to as the         or          and, deals with the physical 
components of the absorbed dose for to accounts the energy released from each 
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radioactive decay and relative geometry of the source organ and the organ for which 
the absorbed dose is to be calculate 67,68,73. The quantity   is given as: 
 (       )   
 
  
 〈 〉 (           )              Equation 20 
where 〈 〉 is the mean energy of the transition per nuclear transition,  (           ) 
is the fraction of radiation energy   emitted within the source tissue    at time   that is 
absorbed in the target tissue    and   is the time-dependent mass of the target tissue 
   in the reference individual. The absorbed fraction,  (           ), for  -particles 
whose range in tissue is short relative to the dimensions of the target tissue is 
approximately 1 and 〈 〉 is typically considered as the mean value of the energy 
spectrum 68. 
The absorbed dose, calculated by integrating the dose rate to target tissue over all time 
is given by the following: 
 (    )   ∫  ̃(    ) (       )  
 
 
                 Equation 21  
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   Equation 22  
From the decay data of 90Y, for an activity of 1 GBq in 1 kg of tissue, and if all of the 
decay energy is completely absorbed within the mass, the absorbed dose can be 
calculated, more precisely, as follows 58,68,70: 
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   Equation 24  
The MIRD schema presents three important phases: the data collection to identify the 
various regions containing activity through counts data acquired with a planar 
scintillation camera, or tomographic SPECT or positron emission tomography (PET) 
system; the data analysis where it is estimated the activity in regions as a function of 
the time using the count data and calibration factors obtained from quantitative 
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measurement techniques; the data processing to integrate of the time-activity curves to 
obtain the sum of all the nuclear transitions, cumulated activity ( ̃) or residence time ( ) 
in each region 69. 
The goal of radiopharmaceutical internal dosimetry is to develop a method to obtain the 
quantitative measures of radiation distribution to the organs while ensuring that 
absorbed dose levels to normal or risk organs are kept below tolerance levels so that 
side effects are minimized 6,67,74. The patient-specific dosimetry, as a standard practice 
in external radiotherapy, can be useful to estimate the efficacy of tumor control and 
predict of toxicity in normal tissue 6,63. However, the implementation of the internal 
dosimetry methodology presents two main challenges. The first is the quantification 
image, by which the counts recorded in an image can be converted to absolute values 
of activity. The activity distribution is obtained using the functional imaging with SPECT, 
which can provide 3D voxel representation that is the activity in each individual voxel 
may be obtained. However, in practice, the finite system spatial resolution and partial 
volume effects causes great uncertainty associated with quantitating radioactivity within 
a small volume. The second question that arises is the absorbed dose calculation due 
the need to deal with problems caused by non-uniform uptake of activity and by non-
standard organ geometries 67,69. Even though there is a limitation in assuming a 
uniform source distribution in the tumor, the current dose calculation is acceptable as a 
first approximation for clinical dosimetry when using 90Y-microspheres 70.  
Ideally, for each radionuclide therapy patient it is necessary or desirable to perform 
patient specific treatment planning due to variability in the delivery of the therapeutic 
agents to tumors and normal liver. A key part of this treatment planning is to include 
pre-therapy imaging with either a surrogate radionuclide (e.g. 111In for Zevalin) or 
imaging agent (99mTc-MAA for 90Y-microspheres) 54,61. In accordance with guidelines of 
the European Association of Nuclear Medicine (EANM), imaging studies with 99mTc-
MAA prior to radioembolization are performed to confirm particle localization, rule out 
extrahepatic shunting to the gastrointestinal tract and lungs, to determinate an optimal 
therapeutic activity and the tumor to liver ratio 56. 
The challenge facing nuclear medicine is to improve the tools and techniques that are 
available to enable absorbed dose calculation to both target and critical organs-at-risk. 
The development of more accurate absorbed dose estimates and the correlation of 
these estimates with biologic response are specially important to a better 
understanding of the results of treatment, improve the clinical outcomes and for the 
safe and effective planning patient treatment of radionuclide therapy 8,71.  
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3. 
 90
Y-microspheres Radioembolization  
Liver cancer is the second most common cause of death from cancer worldwide, 
estimated to be responsible for nearly 746.000 deaths in 2012 1,75. In Europe, around 
63,500 new cases of liver cancer were diagnosed in 2012 76.  
The liver can develop primary liver cancer in a form either of hepatocellular or 
cholangiocellular carcinoma. Moreover, the hepatic metastases also is very common 
from others malignancies such as colorectal cancer, neuroendocrine tumors pancreatic 
carcinoma and breast cancer 4,57,77. The surgery is regarded as the first choice and the 
most effective method of treatment for resection or liver transplantation. But only a 
select group of these patients meets the conditions for resection 56,70,77. In the majority 
of patients the tumor is inoperable at the time of diagnosis because of extrahepatic 
metastasis, bulky volume, location and multicentricity of the tumor 5,70. It creates a need 
to develop other treatments to help to retard tumor progression. That include conformal 
radiation therapy, hepatic arterial infusion chemotherapy, radiofrequency ablation and 
radioembolization 56,66,70,77,78. Radioembolization is an established treatment modality in 
which intrahepatic arterial delivered 90Y-microspheres are used for selective internal 
radionuclide therapy (SIRT) 5,7,79. Currently, two FDA-approved 90Y-microspheres 
products are available commercially worldwide. These microspheres may be 
composed of 90Y doped resin (Sir-Spheres®, Sirtex Medical, Lane Cove, Australia) or 
incorporates 90Y in a glass matrix (TheraSphere®, MDS Nordion, Kanata, ON, Canada) 
(Table 3) 7,56,58,80. The method takes advantage of the unique vascular system of the 
live. Normal liver parenchyma draws approximately 70% - 80% of the organ‘s blood 
flow from portal vein. This is in contrast to the hepatic tumors, which have 80% - 100% 
of their blood supply almost exclusively via the arterial hepatic circulation. This means 
that the delivery of radioactive microspheres can selectively target the liver 
malignancies 56,77,81. 
Radioactive microspheres are biocompatible but not biodegradable and metabolized 82. 
In addition, the radioembolization can provide potential complications such as excess 
extrahepatic deposition of activity, which may include gastritis/duodenitis, 
gastrointestinal ulceration/bleeding, cholecytitis, pancreatitis and radiation pneumonitis. 
And, the excess dose delivered to the healthy liver can leads to the radioembolization-
induced liver disease. The unique aspects of therapy require for each patient certain 
steps of particular importance such as an appropriate imaging, appropriate selection of 
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patients, pretreatment angiogram with selective visceral catheterization, and treatment 
simulation with 99mTc labeled macro-aggregated albumin (MAA), dose calculation, 
therapy, and follow-up 4,7. 
Table 3 - Properties of available commercially 
90
Y-microspheres. 
Description item SIR-Spheres® TheraSphere® 
Sphere material Resin Glass 
Sphere diameter (µm) 20-60 20-30 
Activity in single vial (GBq) 3 3, 5, 7, 10, 15 and 20 
Number of spheres per vial 40-80 x 106 1.2-8 x 106 
Density (g/cm3) 1.6 3.29 
90Y activation mode Carrier-free Reactor 
Assumed activity per sphere (Bq) 50 2500 
Shelf life 24 hours after calibration 12 days after calibration 
Manufacture activity calculation 
recommendations  
Empiric Method 
BSA Method 
Compartmental MIRD 
macrodosimetry (Partition 
Method) 
Non-compartmental MIRD 
macrodosimetry 
3.1. Treatment Planning 
For a successful radioembolization, a proper planning of the procedure is necessary to 
ensure that patients receive a safe and effective 90Y-microspheres delivery 83. The 
main aim for planning the delivery of 90Y-microspheres is minimize radiation damage to 
the extrahepatic structures ensuring that the indication for the treatment is correct and 
helping to deliver the microspheres the right places in the liver 84. 
Careful patient selection and preparation for 90Y liver-directed therapy result in an 
optimal risk/benefit ratio for the patient. Treatment planning for implantation of 90Y-
microspheres is typically a 2-stages process, a simulation of the actual treatment with 
99mTc-MAA particles that are roughly the size of the microspheres and 1-2 weeks later 
an implantation phase 85. 
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3.1.1. Patient Selection 
The candidates referred for SIRT include patients with non-resectable hepatic primary 
or metastatic cancer that do not respond adequately to other treatment modalities such 
as transplantation, radiofrequency ablation or transarterial chemoembolization. A 
comprehensive understanding of the general clinical condition of patient , as described 
by the Eastern Cooperative Oncology Group (ECOG), laboratory test results, treatment 
history, and potential future treatment options is critical in patient selection 5,86.  
Treatment with 90Y-microspheres must be based on careful review of screening tests of 
the individual patient. The initial workup should include cross-sectional multi-phase CT 
or magnetic resonance (MR) imaging of the liver for assessment of tumoral and 
nontumoral volume, the radiologic staging of disease including number, size, and 
localization of tumor, portal vein patency, and presence of extrahepatic disease. In 
addition, molecular imaging with SPECT/CT or PET/CT can be very helpful 5,7,83. 
Serum chemical analyses should be performed to evaluate hepatic and renal function 
and to determine the presence tumor markers. In general, relative contraindications to 
treatment with 90Y-microspheres include limited hepatic reserve, irreversibly elevated 
bilirubin levels, compromised portal vein (unless selective or super selective 
radioembolization can be performed), and prior radiation therapy involving the liver. 
Sufficient hepatic function is of primary importance and is regarded as the greatest 
limitation (Child–Pugh score ≤ B7). The renal status should be also adequate to 
accommodate the use of contrast agents during the diagnostic and the therapeutic 
angiogram 83,87.  
All patients should be selected according to strict inclusion/exclusion criteria and, need 
to be assessed by a multidisciplinary team (Table 4) 7,83.  
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Table 4 - Indications and contraindications for Radioembolization.   
Indications Contraindications  
Disease nor amenable to surgical 
resection, liver transplantation or ablative 
therapies. 
Extensive and untreated portal 
hypertension. 
Compensated or early decompensated 
liver cirrhosis (Child-Pugh ≤ B7). 
Active hepatitis. 
Performance stage ≤ 2. 
Extrahepatic deposition of 99mTc-MAA (i.e. 
gastrointestinal tract). 
Life expectancy > 3 months. 
Anticipated lung exposure to 90Y radiation 
>30 Gy based on pre-treatment 99mTc-
MAA scan. 
Liver only or liver dominant disease. 
Excessive tumor burden with limited 
hepatic reserve. 
Preoperative indications. 
Elevated total bilirubin level (2 mg/dL) in 
the absence of a reversible cause. 
3.1.2. Angiogram and Therapy Simulation with 99mTc-MAA 
SIRT is a flow-directed therapy that relies upon neoangiogenesis and increased blood 
flow in malignant tumors to preferentially take up 90Y-microspheres from the hepatic 
arterial circulation 5. Once the patient has been selected as a potential candidate, a 
pretreatment hepatic arteriography and hepatic arterial perfusion (99mTc-MAA) are 
performed before radioembolization. The aim of the initial angiographic assessment of 
the vascular anatomy is identify the vascular supply of the liver and the tumor; identify 
and embolize vessel that may lead to non-target deposition of the radioembolic 
material; determine the procedure termination for the microspheres 58,86. Flow 
characteristics in the hepatic artery should be detected and extrahepatic deposition of 
the microspheres is prevented by arterial catheters inserted percutaneously under 
fluoroscopy by the interventional radiologist. Meticulous technique is required to 
embolization of all relevant vessels including superior mesenteric, gastroduodenal and 
right gastric, right and left hepatic artery and other extrahepatic vessels given the 
possibility of non-target deposition of microspheres. It is important to note that these 
vessels/organs can revascularize quickly, and therefore the embolization should be 
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performed close to the anticipated treatment date, realizing a check arteriogram before 
radioembolization to ensure that such revascularization has not occurred 83.  
Once the mapping and embolization steps are completed and the treatment location 
identified, 99mTc-MAA (111 MBq – 185 MBq) is injected through the catheter by a 
nuclear medicine physician in a slow-pulse over several minutes. The infusion of 99mTc-
MAA is used to predict the distribution of the 90Y-microspheres prior to treatment 88. 
The patient is then taken to a gamma camera where planar imaging and SPECT of the 
upper abdomen are acquired to confirm particle localization and rule out extrahepatic 
shunting to the gastrointestinal tract and lungs 10,86. The lung shunt fraction (LSF) is 
calculated using planar images in anterior and posterior projections (Figure 17), given 
from the total counts within regions of interest (ROI) over both lobes of the lung (     ) 
and entire liver counts (      ) (Equation 25) using the geometrical mean of images. 
The extrahepatic shunts were noted on both planar and SPECT images. Moreover, 
SPECT constitutes the basis for image fusion with other pre-/post-therapeutic 
tomographic images as CT or MR 58,89. 
  
Figure 17 - Planar gamma camera with ROI draw. (I) Planar transmission/emission image with planar phantom 
for anatomical location of the lungs. (II) Planar emission image for the calculation of the LSF. 
     
     
             
         Equation 25  
Patients in whom the hepatopulmonary shunt fraction (LSF) is greater than 20% of the 
injected activity (Table 5) or in whom the shunt fraction indicates potential exposure of 
the lung to an absorbed radiation dose of more than 30 Gy can be excluded from the 
use of microspheres due to the possibility of radiation pneumonitis. In patients with a 
I II 
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LSF less than 20% a reduction in the total administered activity is necessary 58. In 
short, the 99mTc-MAA should ideally be delivered selectively into the hepatic circulation 
to simulate as closely as possible the planned 90Y radioembolization, allowing accurate 
determination of any likely pulmonary breakthrough. 
Table 5 - Percentage of shunting to the lungs. 
Percent Lung Shunting Activity of 90Y (GBq) 
< 10% Deliver full amount of 90Y-microspheres 
10% to 15% Reduce amount of 90Y-microspheres by 20% 
10% to 20% Reduce amount of 90Y-microspheres by 40% 
>20% Do not give 90Y-microspheres 
3.2. Activity and Dose Calculation  
Radioembolization usually induces tumor regressions of varying degrees in selective 
regions. The biological effects of therapy with microspheres are heavily dependent of 
two components: Dose and Activity. Dose (Gy) is specifically defined as the energy 
absorbed per unit mass of tissue. In SIRT, the absorbed dose depends on the amount 
of 90Y activity (GBq) delivered to the target organ. The activity is a constant value, but 
how microspheres distribute inside the liver after injection is influenced by 
hemodynamics of the hepatic artery blood flow and the vessel density inside the 
tumors 79. 
Therapeutic efficacy is closely related to the injection activity of 90Y-microspheres. 
Currently, two 90Y-microspheres products are available commercially, which are made 
of resin (SIR-Spheres®) or glass (TheraSpheres®) 56. The required activity for treatment 
of each patient is to be calculated differently according to whether glass or resin 
microspheres are to be used. For resin microspheres the manufacturer‘s user‘s manual 
(Sirtex user‘s manual) suggests three methods of estimating the activity to use for resin 
microspheres treatment: Empiric Method, Body Surface Area Method, Partition 
Method. In contrast, the for 90Y glass microspheres have only one method for activity 
calculation.  In common, the four methods have suggested reducing the prescribed 90Y 
resin microspheres activity if the lung shunt fraction (LSF) is upper 10%, in order to 
lower the radiation risks to the lungs, because a correlation exists between the 
administered activity and the lung shunt fraction (Table 5) 9,82,90.   
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3.2.1. Glass microspheres 
TheraSpheres® was approved by the FDA in 1999, with indication for radiation 
treatment or as a neoadjuvant to surgery or transplantation in patients with 
unresectable HCC. This therapeutic device consists of insoluble glass microspheres 
where 90Y is an integral constituent of the glass 87.  
The activity for administration of glass microspheres relates directly to the desired 
absorbed dose. A typical dose between 80 Gy and 150 Gy should be delivered to the 
treated liver. This wide range allows a treating with clinical flexibility, where patients 
with cirrhosis should be treated more conservatively (80 – 100 Gy); whereas patients 
without cirrhosis may be treated with more dose (100 – 150 Gy). Treatment planning 
using 99mTc-MAA predicts a target tumor dose at least 205 Gy. It is recommended that 
the lung dose be less than 30 Gy or 50 Gy for cumulative treatments to prevent 
radiation pneumonitis. Assuming that glass 90Y-microspheres has uniform distribution 
in throughout the liver and 90Y undergoes complete decay in the liver, one single 
method is proposed by the manufacturer for activity calculation, and is based in MIRD 
formalism 7,82,87,91:  
       (   )   
               
       
   Equation 26  
where         (Gy) is the absorbed delivered dose to the target liver mass and         
(kg) is the mass of the target liver mass. Equation 26 not takes into account adjustment 
to the 90Y activity based on LSF. However, a fraction of the microspheres will flow into 
the pulmonary circulation, when LSF and vial residual is taken into account, the actual 
doses in the selected volumes of interest (i.e. tumor and healthy liver) after the vial is 
infused are calculated using the following formula 91,92. 
  (  )   
                 (       ) 
       
    Equation 27  
After administration of 90Y-microspheres, the percentage of injected activity ( ) 
remaining in the dose vial, inlet and outlet catheters of the delivery device should be 
determined for calculation of the actual dose. The LSF is calculated beforehand by 
using 99mTc-MAA scintigraphy. It is noted this dosimetry model is independent of tumor 
burden 87. See Table 3 for more detailed data. 
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3.2.2. Resin microspheres 
SIR-Spheres® were granted premarket approval by the FDA in 2002, with indication for 
the treatment of unresectable metastatic liver tumors from primary colorectal cancer 
with adjuvant intra-hepatic artery chemotherapy of Floxuridine (FUDR). SIR-Spheres® 
is a device with two components, resin based biocompatible microspheres containing 
90Y 58,87,93.  
For the resin microspheres, the manufacturer (Sirtex) proposes three alternatives to 
decide 90Y activity. Just as with TheraSphere®, assumes SIR-Spheres 90Y-
microspheres are homogeneously distributed throughout the liver 58. 
3.2.2.1. Empiric Method Calculation 
The first method proposed by SIR-Spheres is the Empiric Method and was devised on 
the intraoperative calculations from beta probes of early clinical trials94–97. The activity 
calculation to be used in treatment is based solely on an estimate of tumor involvement 
(IT) (Equation 28). The volume of the tumor (VT) and the volume of the normal liver 
(VNL) were calculated on computed tomography performed by manual slice by slice 
contouring. In case of lung shunt is less than 10%, the empiric method recommends 
three different activities presented in Table 6 9,56,62,83,87,98. This method is not the most 
recommended because it has a crucial limitation that are an individual characteristics of 
patient is not considered and presents a higher risk of radioembolization-induced liver 
disease 83,99. However, it cannot be considered that the empiric method is not useful, 
since through it was possible to establish an upper limit of activity to be injected 
according to the clinical conditions previously developed 79. 
  ( )  
  
       
         Equation 28  
Table 6 - Activity recommendations. 
Percent Tumor Volume Activity of 90Y (GBq) 
< 25% 2,0 
25% to 50% 2,5 
> 50% 3,0 
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3.2.2.2. Body Surface Area Method Calculation 
The activity calculation most widely used for 90Y resin microspheres has been the body 
surface area (BSA) method based in empiric method. The second method is 
recommended by the manufacturer (Sirtex) and has been used safely in clinical trials 
97. The BSA method takes into account the patient‘s BSA, that is, the patient‘s weight 
(W) and height (H), as well as the VT volume and VNL volume, assuming a correlation 
between BSA and tumor involvement 9,62,65,82,87. According to the Dubois and Dubois 
the formula for BSA is described as 100,101: 
    (  )              ( )         (  )        Equation 29  
This model assumes that the size of each patient‘s liver correlates with the BSA, 
leading to a proportional activity adjustment (Equation 30) 7,9,65,66. As in the empiric 
method the activity calculation requires the normal liver and tumor volume from the CT 
scan 90.  
  (   )  (       )  (
   
       
)   Equation 30  
The BSA method is used due its simplicity, presenting objective responses e low 
incidence of toxicity. Nevertheless, its main limitation is the absence of the tumor-to-
normal liver (T/N) ratio, which can result in underdose for patients with larger livers and 
overdose for patients with small liver 7,8,56,65. The T/N ratio exposes on the tumor-to-
normal uptake ratio of the therapeutic radiopharmaceutical give a more patient-specific 
and scientifically sound estimate the proportional microspheres distribution in the tumor 
8,9,102.   
3.2.2.3. Partition Method Calculation 
According to Sirtex, the Partition Model (PM) is another method for calculation of 
dose/activity 90. The Partition Method provide the mathematic derivations of the 
equations used in the Medical Internal Radiation Dose (MIRD) formalism developed by 
the Committee of the Society of Nuclear Medicine, as previously mentioned 58,66,71.  
Ho et al, using the MIRD formula, formulated partition model for estimating radiation 
doses to the lungs, tumor and normal liver parenchyma discriminatively and verified the 
activity distribution by intraoperative measurement 103,104. The partition model 
incorporates tissue masses and a measurement of the tumor-to-normal liver (T/N) ratio. 
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It requires separation of the organ system into compartments (lungs, tumor and non-
tumorous liver). This because, the distribution profile of the 90Y-microspheres activity is 
determined by the relative vascularity and volume of the tumor and normal liver 
compartments, which is expressed as the tumor-to-normal liver (T/N) ratio. And, when 
lung shunting due to intrahepatic peritumoral arteriovenous communication occurs, a 
third compartment (lung) is expressed as the lung shunt fraction (LSF) 71. The LSF is 
calculated on planar images using the formula below:  
    
          
                            
          Equation 31 
The determination of the percentage of pulmonary shunt may require that there be a 
modification to the 90Y activity determined or, for patients with > 20% pulmonary 
shunting precludes use of SIR-Spheres microspheres (Table 5) 90. 
The percentage of activity shunted to the lung, the evaluation of extrahepatic 
deposition and the tumor-to-normal liver (T/N) ratio (Equation 32) are determined from 
pre-therapeutic planar and SPECT images acquired using 99mTc-MAA with the aim to 
predict the intrahepatic distribution of 90Y-microspheres used in subsequent treatment 
and hence radiation dose to each compartment 10,90,103,105. The nuclear medicine scan 
is performed in all patients.  
      
     
       
    Equation 32 
In 90Y therapy, it is assumed that 90Y-microspheres will follow the MAA distribution. 
However, there are great uncertainties associated with this approach, for the 
distribution of radiotracer between these paired studies does not always match. 
Parameters that may influence distribution differences between 99mTc-MAA and 90Y-
microspheres include the reproducibility of catheter position during therapy; the 
different characteristics of 99mTc-MAA and resin 90Y-microspheres, physiologic 
variances in hepatic blood flow, tumor histopathology and tumor load. In radionuclide 
therapy, the absorbed dose is generally estimated, because in vivo dose measurement 
is not practicable in clinical settings. And, without accurate patient dosimetry, it is 
impossible to establish fundamental dose-response relationship for treatment efficacy 
and toxicity 10,88,106,107. 
The PM involves implanting the highest possible activity to the tumor while maintaining 
radiation dose to the healthy liver and lung within acceptable limits. Thus, the maximal 
activity to be administered in order to preserve normal liver and lung are calculated 
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using the equations Equation 33 and Equation 34. The activity required should be 
calculated using the lung dose recommended as the limiting factor, and then again 
using the normal liver dose recommended as the limiting factor. The lower of the two 
activities calculated should be used 66,90.  
       (    )   
                
   
   
      
    Equation 33 
 
       (     )   
            (      )      
        (   
   
   
)
    Equation 34 
where      is the tolerance absorbed dose for healthy tissues,          and     
represents the volumes obtained from CT scan for lung, normal liver and tumor 
respectively,     is the lung shunt fraction and     is the ratio between tumor and 
normal activity per unit mass. All activities are in GBq and the volumes, with the 
approximation of mass equal to volume, in dm3. The lung is largely filled with air then, 
the CT scan cannot be used to measure the volume of lung, assuming thus an 
estimated volume of 1 dm3 66,90,103. The recommendations found in literature suggested 
that 30 Gy could be the limit for the tolerance absorbed dose to the lungs 66,104. 
However, the SIR-Spheres® User Manual recommend that pulmonary radiation doses 
during SIRT should preferably remain below the 25 Gy 90. The manufacture and the 
literature suggested that the normal liver can tolerate radiation up 80 Gy, but in patients 
with cirrhotic liver the limit should not exceed 70 Gy 90,104,108. The non-resectable HCC 
is radioresistent and, therefore, it is necessary to implant absorbed doses for tumor 
response is at least 120 Gy 56,104. However, there is a limitation in delivered doses 
because it can cause severe injury to the surrounding tissue, including the liver 
parenchyma and duodenum 109. 
The total activity, Atotal, of 
90Y-microspheres delivered to a patient is distributed in three 
discrete vascular compartments. As seen previously, the MIRD schema can be used to 
calculate the absorbed dose on tissue, given that is analytical calculation available at 
this time and, suggested by manufacture SIR-Sphere®. According to the basic 
dosimetry formula of 90Y-microspheres and radioactivity distribution, the absorbed 
doses are expressed as 56,66,90: 
       
              (
   
   
)
     
    Equation 35  
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    Equation 36 
                Equation 37 
In clinical practice, the Partition Model is suggested as an alternative means of activity 
calculation in patients with a tumor mass localized in a discrete area within the liver and 
the tumor can be delineated as a region-of-interest on a SPECT camera image. This is 
recommended in majority of cases to patients with HCC where there is often a large 
single tumor mass. In contrast, patients with metastatic disease usually have multiple 
areas of metastatic where it presents ill-defined margins that precludes defining the 
tumor and normal liver 9,90. 
Among those methods, the PM method based on 99mTc-MAA imaging is the most 
personalized, with the development of more accurate absorbed dose estimates. The 
correlation of these estimates with biologic response will lead to a better understanding 
of the results of treatment and improve the clinical outcomes 57,71. 
3.2.2.4. Body Surface Area Method versus Partition Method  
Different methods have been developed and used for activity calculation and 
prescription. For resin microspheres, the BSA method and the partition method can be 
both be used for 90Y activity calculation. The manufacturer‘s recommendation for the 
use of PM did not appear to be intended for diffuse tumor 65,90. 
The BSA method is the most common in clinical trials due its simplicity and has been 
used safely, with objective responses and low incidence of toxicity 110. The calculated 
activity of the whole liver is correlated with the percentage of the target site as a 
proportion of the whole liver. Furthermore, the BSA method neglects the individual 
intrahepatic distribution differences, calculated by the activity concentration ratio 
between lesion and healthy liver (T/N), which can expose patients to the risk of 
unnecessary toxicity or tumor underdosage 56,65,66. The estimated T/N ratio can predict 
the success or failure of 90Y radioembolization and, its embedding in the activity 
calculation will lead to a higher administered activity and higher tumor dose without 
compromising healthy liver tissue 7,8. The semi-empiric method may has limitations with 
90Y activities, because will almost always derive activities ranging between 1.0 and 3.0 
GBq. This is because, for example, to small patient who is 1.4 m tall, weighs 40 kg and 
has 1% tumor involvement the 90Y activity will yield 1.0 GBq. On the other limit a large 
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patient who is 1.9 m tall, weighs 100 kg and has 90% tumor involvement will yield an 
estimated 90Y activity of 3.0 GBq 8. The advantages and disadvantages of the Body 
Surface Area method are summarized in Table 7.  
The partition model was developed by Ho et al. and is validated for calculated 90Y resin 
microspheres activity based on MIRD formalism. This method takes most relevant 
factors in account, based on anatomical information but also on the targeting pattern 
and uptake intensity obtained from 99mTc-MAA 56,66,82. This planning treatment needs 
volume measurement of the liver and tumor tissue and defines compartments (lung, 
tumor and normal liver) for radiation dose calculation. The estimated T/N ratio it also 
incorporate to give a more patient-specific and scientifically sound estimate of the 
radiation dose delivered to each compartment 8,11. Partition modeling allow for much 
greater physician flexibility in radiation dose planning, beyond the traditional fixed 
approach of percentage lung shunting and related empirical adjustments to the desired 
90Y activity. However, the literature recommends that PM be applied to solitary hepatic 
tumors or multifocal lesions if each can be adequately localized. The partition model is 
the safe, effective and individualized radiation therapy planning 8,9,90,102,103. The 
advantages and disadvantages of partition method are summarized in Table 8. 
 
Table 7 - Advantages and disadvantages of the Body Surface Area method 
Advantages Disadvantages 
Simple and user friendly Less personalized than partition modeling 
Strong historical data of clinical 
Use 
Low scientific basis. Not a true ‗dosimetric‘ 
method 
Recommended for use in subcentimeter 
tumors or tumors with ill-defined 
margins, by visual estimation of the 
overall tumor burden 
The desired 90Y activity in cases of high 
liver-to-lung shunting is adjusted empirically 
using standard reference tables provided by 
the manufacturer 
 
Artificially limits the injected 90Y activity 
between 1.0 and 3.0 GBq 
 
Tumor radiation dose (Gy) is unknown 
unless the estimated T/N ratio also is 
calculated 
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Table 8 - Advantages and disadvantages of the partition method. 
Advantages Disadvantages 
Personalized dosimetry More complex and resource intensive 
More scientifically sound than the BSA 
method 
Less historical clinical data as compared 
to the BSA method 
The desired 90Y activity in cases of high 
lung shunting is adjusted on the basis of 
predicted lung radiation dose (Gy)  
More appropriated for single or discrete 
tumors  
No theoretical limit to the 90Y activity to be 
injected  
 
Greater control over radiation dose (Gy) to 
lung, liver and tumor compartments 
 
 
 
The partition method is recommended in the majority of cases, but is not currently 
feasible in patients with diffuse metastatic disease with ill-defined margins. 99mTc-MAA 
scintigraphic resolution in subcentimeter tumor sizes may not be adequate for accurate 
tumor ROI delineation in T/N ratio estimation. For very small tumor masses and tumor 
with diffuse margins the BSA method is more suitable 8,65.  
The BSA method and the PM have common limitation this because both were 
formulated on the assumption of uniform resin microsphere distribution within tumor 
and normal liver compartments. Nonetheless, the actual distribution of microspheres 
may be non-uniformly distributed across the liver, with preferential deposition at the 
tumor periphery. The effect of radiation cross-fire must also be considered. These 
issues create complex dosimetric problems requiring specialized medical physics 
teams and computed power. Even with the limitation presented the partition method is 
technically superior to the BSA method 8,82. 
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3.3. 90Y-microspheres Therapy 
The 90Y-microspheres implantation involves repeating the catheterization procedure on 
the treatment day. The activity of 90Y-microspheres to be implanted is dependent on 
factors such as type of spheres used (SIR-Spheres or TheraSphere), properties of the 
target site (primary liver cancer or metastatic tumors) and the level of LSF derived from 
99mTc-MAA scan 56. 90Y-microspheres are then infused through the hepatic arteries 
under fluoroscopic guidance, with caution paid to any reflux of spheres. This is 
because the arterial flow dynamics vary considerably throughout the radioembolization 
procedure due both to the embolic load of the microspheres and to vessel reactivity in 
the presence of the microcatheter and the perfusion pressure applied during infusion. 
In this way, the microspheres administration should be as smooth as possible and 
constant vigilance are essential to minimizing any turbulent flow or unanticipated jets, 
which may dislodge the catheter tip from its desired location and/or propel 
microspheres into unplanned vessels. However, is essential to sustain sufficient 
pressure and flow to maintain a fairly uniform microspheres suspension avoiding 
‗settling out‘ in the vial, delivery tubing or catheter. The administration may be done 
with alternating injection of infusion solution and contrast medium, in order to maintain 
fluoroscopic surveillance of changing flow dynamics throughout the procedure 5. 
In 90Y therapy, as mentioned before, it is assumed that the 90Y distribution will be the 
same as that for the 99mTc-MAA. However, the correlation between 99mTc-MAA and 90Y 
distribution can vary. There are several factors that may have caused the disagreement 
between these activity distributions including differences in catheter position, injection 
technique, progress of disease between 99mTc-MAA and 90Y studies and difference in 
energy radiation between Bremsstrahlung and 99mTc. In addition, the number, density, 
size and morphology of the radiopharmaceuticals may also have resulted in a different 
activity distribution 10,106. Despite the variability which may occur in the distribution of 
90Y activity are important followed accurate dosimetry and the pre-defined strategy to 
avoid non-hepatic deposition of microspheres 5. 
After the procedure is complete, the patient is again taken to a gamma camera and 
planar and SPECT images of the liver can be performed using 90Y Bremsstrahlung 
imaging. A precise evaluation of microsphere deposition after treatment is critical to 
exclude non-targeted microspheres deposition and to evaluate the radiation absorbed 
dose delivered to the tumor 58. 
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4. Material and Methods 
90Y is widely used in targeted radionuclide therapy and usually imaged with SPECT by 
recording the Bremsstrahlung x-ray of the  -decay, the energy spectrum of which is 
continuous. However, Bremsstrahlung SPECT imaging does not have adequate 
resolution for dose distribution. This because the continuous shape of the x-ray 
spectrum induces the presence of a significant fraction of scatter rays in the acquisition 
energy window, reducing the accuracy of biodistribution and of dosimetry assessments. 
In this way, SPECT image that is obtained prior to the treatment following hepatic 
infusion of 99mTc-MAA can be used to provide data regarding the T/N ratio uptake. This 
data could potentially be appropriate in dose calculation. In addition, the 99mTc-MAA is 
primarily used for LSF analysis and evaluation of extrahepatic deposition, with the aim 
to predict intrahepatic post-therapy 90Y-microspheres distribution.  
In this study, the main focus goes to the resin microspheres. 
4.1. Pretreatment imaging and dosimetry 
99mTc-MAA scintigraphy is made at the time of the pretreatment angiography to quantify 
the LSF and to detect any extrahepatic deposition of activity. Pre-treatment imaging 
was performed on a dual-head  -camera, e.cam (Siemens Health Care). Static planar 
imaging is done with low energy, high resolution, and parallel-hole collimator capable of 
obtaining conjugate anterior and posterior images of the patient. Typically, two static 
images are acquired, one with planar phantom positioned in posterior and other without 
planar phantom. These images capture the liver and lungs and, the position of the 
detector and of the patient not change during the images acquisition. Regions-of-
interest (ROI) over the whole liver and lungs are drawn on the actual image using the 
ImageJ program1; the image with planar phantom will help with the ROI outline. A 
planar image is illustrated in Figure 18, with typical scan parameters listed in Table 9. 
Both planar acquisitions, with and without planar phantom, are obtained using the 
same protocol. The ROI counts for each region are recorded and the lung shunt is 
calculated as described in section 3.2.1.  
                                               
1
 ImageJ is an open source, Java-based image processing program developed at the National Institutes of Health. It can 
display, edit, analyze, process, save and print many image formats including TIFF, GIF, JPEG, BMP, DICOM, FITS and 
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Figure 18 - Planar gamma camera image with ROI. (I) Planar transmission/emission image with planar phantom 
for anatomical location of the lungs. (II) Planar emission image for the calculation of the LSF. 
After obtaining planar images, the distribution of the microspheres in the liver was 
assessed on the SPECT images. SPECT images of the abdomen are acquired on an 
e.cam (Siemens Health Care) by rotating gamma detectors around a patient and, 
subsequently reconstructed using reconstruction software. LSF are calculated using 
planar images, and extrahepatic activity is noted on both planar and SPECT images. In 
SPECT base dosimetry, the 99mTc-MAA particles are used as surrogates for 
microspheres to assess to microsphere distribution within the liver. For this, software 
tools perform three-dimensional registration of images sets providing geometric 
correlations of the activity data with patient anatomy. The uncertainty in the geometrical 
correlation recommends the use of SPECT/CT fusion images (Figure 19). The typical 
SPECT acquisition parameters are given in Table 9. SPECT imaging data was 
reconstructed using an iterative method (2D OSEM, 8i, 4s, 6mm Gaussian filter), and 
images were then visualized with and without fusion with CT scan data.    
Table 9 - Static planar imaging and SPECT protocols, using 
99m
Tc energy specification.  
Parameters Planar 99mTc-MAA SPECT 99mTc-MAA 
Zoom 1 - 
Matrix 256x256 128x128 
Azimuth angles - 64 
Counting time 300 s 30 s per angle 
Energy window 140 keV (15%) 140 keV (15%) 
Collimator Low Energy Low Energy 
 
I II 
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Figure 19 - Pretreatment 
99m
Tc-MAA SPECT image. 
In tumors where the radionuclide distribution and the tumor the can be easily 
delineated on imaging studies, the tumor-to-liver activity uptake can be estimated from 
the 99mTc-MAA study. Volume measurements of liver and tumor were carried out on CT 
images using ARIA data-processing console display with ―Contouring‖ software (Figure 
20). The count measurements were conducted on the SPECT images using ImageJ 
program. A ROI was drawn in each axial slice encompassing the tumor (ROI_1), and 
the same is done to the liver (ROI_2). The normal liver counts were obtained by 
subtracting liver and tumor counts. All delineated ROIs were manually registered to the 
99mTc-MAA SPECT with help of contrast-enhanced CT scan for segmentation (Figure 
21).  
  
  
Figure 20 - (I) Segmentation of liver and tumor on CT scan. (II) Representative liver from segmentation. (III) 
Representative tumor from segmentation. 
I 
II III 
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Figure 21 - Representative axial SPECT image to calculate the T/N ratio. CT and 
99m
Tc-MAA/SPECT images with 
ROI surrounding the entire liver and the treated tumor. 
These ROIs were then used to measure the activity distribution (expressed in counts), 
where the T/N is calculated as the tumor-to-liver counts over the corresponding ROIs. 
Mathematically the T/N is calculated using the Equation 32. 
The activity and dose absorbed by the tissues of interest (lung, normal liver and tumor) 
were calculated based on the partition method (section 3.2.2.3) for three cases. Where 
the injection positions of 99mTc-MAA and 90Y-microspheres also are analyzed. In 
addition, sixty four patients evaluated for radioembolization were retrospectively 
analyzed. The activity of 90Y-microspheres administered to all patients was calculated 
by the method recommended by the company Sirtex, based on the body surface area 
and the percentage of perfused liver volume and percentage of liver volume occupied 
by the tumor (section 3.2.2.2). 
4.2. Evaluation of Bremsstrahlung imaging  
Treatment efficacy of radioembolization is assessed by the 90Y Bremsstrahlung SPECT 
imaging. Post-therapy SPECT image has the potential of providing reliable activity map 
of 90Y-microspheres distribution. However, these images demonstrate a poor image 
quality. Quantitative Bremsstrahlung imaging is very difficult to obtain due scatter, 
septal penetration, the continuous nature of the Bremsstrahlung energy spectrum, and 
inefficient Bremsstrahlung production. In literature, several image acquisition 
parameters and subsequent different reconstruction protocols are suggested 60,61. With 
the aim to obtain an appropriate 90Y Bremsstrahlung SPECT imaging was evaluated 
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several reconstruction methods. 90Y SPECT images were acquired using a gamma 
camera (e.cam, Siemens) equipped with a medium energy general purpose parallel-
hole collimator and an energy window of 136-184 keV. The acquisition parameters of 
90Y Bremsstrahlung SPECT are present in Table 10.  
Table 10 - SPECT imaging protocol for 
90
Y Bremsstrahlung post-implanting studies. 
Parameters 90Y-Bremsstrahlung 
Acquisition matrix 128x128 
Azimuth angles 64 
Counting time 30 s per angle 
Energy window 160 keV (15%) 
Collimator MEGP 
4.2.1. Phantom study 
90Y Bremsstrahlung image was acquired with activity uniformly distributed in the line 
source placed inside a Jaszczak phantom (Standard Jaszczak PhantomTM, Data 
spectrum Corporation, Durham, NC) (Figure 22). The phantom was filled with water 
and a line source contained 222 MBq was placed inside in the longitudinal direction. 
The projections were acquired using the same protocol acquisition for post-therapy 
study (Table 10). 
 
 
Figure 22 - (I) Line source with activity uniformly distributed. (II) Jaszczak Phantom with line source used in 
physical experiment. 
I 
II 
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For each reconstruction parameters was applied a 2D Gaussian function approximation 
to create simulated data in order to explore the SPECT resolution (FWHM)2. A square 
ROI was delineated on SPECT slice and the data collected to plot the 2D profile of the 
experimental data (Figure 23).   
 
Figure 23 - Axial SPECT slice from experimental measurement.   
Image contrast and noise measurements also were obtained from phantom experiment 
reconstructions. A circular ROI was drawn in hot region and four background ROIs 
were delineated on the same slice that fell within the physical phantom boundaries on 
the reconstructed image (Figure 24). The same ROIs and slices were used to analyze 
all the reconstructed images of the phantom. 
 
                                               
2
 A Gaussian shape seems to the appropriate for FWHM calculation in this situation (Santos et 
al 2008 and Pasciak et al 2014).  
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Figure 24 - Axial SPECT slice from experimental measurement for noise and contrast measurements. 
For each reconstructed SPECT volume, contrast recovery coefficients were calculated 
with Equation 38.  
         ( )   |
      ̅̅̅̅
      ̅̅̅̅
|         Equation 38  
where    is the counts in the hot region (ROI_1) and   ̅̅ ̅ is the mean counts in the 
background ROIs (ROI_2, ROI_3, ROI_4, ROI_5). A measure of image noise was 
calculated with Equation 39. 
      ( )  
    
  ̅̅̅̅
         Equation 39  
Here,      is the standard deviation in the background ROIs. The     was calculated 
with Equation 40. 
      √
 
 
∑ (     ̅) 
 
       Equation 40 
The counts per voxel are another factor strongly dependent on the method of 
reconstruction. Hence, the relative SPECT counts in each voxel of the image were 
converted to absolute activity by normalizing the total counts minus background to the 
total 90Y administered activity as: 
                
      
          ̅̅̅̅
    Equation 41 
where        is the present activity in the line source (222 MBq).  
Posteriorly, to investigate the feasibility of Bremsstrahlung imaging in a real patient 
situation, a SPECT reconstruction that presented better results was conducted on a 
patient undergoing standardized treatment with 90Y-microspheres. 
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5. Results and Discussion 
5.1. Pretreatment imaging and dosimetry 
A total of sixty two patients were evaluated for radioembolization after the 99mTc-MAA 
procedure and were treated with resin microspheres. The diagnoses included 
hepatocellular carcinoma, neuroendocrine tumors metastatic to the liver and metastatic 
liver tumors from other primary tumors including colon, lung, breast or rectal cancer. 
For all delivered treatments, a retrospective analysis was performed, presented in the 
Table 11. 
Table 11 - Patient characteristics. 
Parameters Data 
Sex (n)  
    Male 45 (72.58%) 
    Female 17 (27.42%) 
Weight (kg) 71.84 ± 14.09 
Height (m) 1.69 ± 0.07 
Primary tumor (n)  
    Hepatocellular  23 (37.10%) 
    Cholangiocarcinoma 21 (33.87%) 
    Colorectal 4 (6.45%) 
    Neuroendocrine 4 (6.45%) 
    Others 10 (16.13%) 
Tumor involvement (n)  
    <25% 23 (37.10%) 
    25% - 50% 33 (53.23%) 
    50% - 75% 6 (9.68 %) 
    75% - 100% 0 (0%) 
Lung Shunt Fraction (n)  
    <5% 20 (32.26%) 
    5% - 10% 31 (50.00%) 
    10% - 15% 9 (14.52%) 
    15% - 20% 2 (3.23%) 
Treatment  
    Whole liver 48 (77.42%) 
    Lobar liver 14 (22.58%) 
Resin microspheres activity (GBq) 1.70 ± 0.42 
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Between 2011 and 2017, these treatments were delivered, and the injected activity was 
calculated with BSA method. Lobar and whole liver treatments were analyzed 
separately as function of tumor involvement (Figure 25). The injected activities in whole 
liver treatments present a relative shorter range, where the maximum activity was 2.47 
GBq and the lowest activity was 1.24. While the maximum activity administered in lobar 
treatment was 1.93 GBq and the minimum 0.65 GBq. In each graph was represented 
the mean ± standard deviation of the analyzed data. 
 
  
Figure 25 - Calculated activity from BSA method as function of tumor involvement. (I) For whole liver 
treatments. (II) For lobar treatments.  
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In this retrospective study, eleven evaluations presented a shunt greater than 10%. For 
these patients, with significant pulmonary shunting, the prescribed activity was reduced 
according to recommendations of the manufacturer (20% reduction for LSF: 10% - 
15%; 40% reduction for LSF: 15% - 20%). The separated analysis of whole liver and 
lobar treatments as function of tumor involvement is presented in Figure 26.  
 
  
Figure 26 - LSF as function of tumor involvement. (I) For whole liver treatments. (II) For lobar treatments. 
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In clinical routine, the injected activity was calculated with the BSA method. The idea is 
to evaluate some cases to understand the influence of the method used to calculate 
the activity. 
The first case study is a patient with a hepatocellular carcinoma, the most frequent 
treated pathology, involving more than 30% of the evaluations. This patient presented a 
voluminous HCC infiltrating almost the entire right lobe.  After pre-treatment with 99mTc-
MAA a pulmonary shunt fraction of 13% forced the reduction of activity to be 
administered. With 99mTc-MAA/SPECT it is also possible see accumulated 99mTc at the 
periphery of the lesion in the right lobe. Table 12 summarizes the tumor volume, LSF, 
administered 90Y activity, and lung, liver, and tumor dosimetry in each target volume, 
calculated from PM and BSA method. 
Table 12 - Summary of the characteristics of the case 1. 
CASE 1 
Pathology: Hepatocellular Carcinoma 
LSF: 13.10 % 
Tumor involvement: 34 % 
T/N: 2.74 
 Partition Method BSA Method 
Activity to be administered GBq) 2.65 1.27 
Activity Normal Liver (GBq) 0.96 0.46 
Dose Normal Liver (Gy) 50.00 23.91 
Activity Tumor (GBq) 1.35 0.65 
Dose Tumor (Gy) 136.81 65.42 
Activity Lung (GBq) 0.35 0.17 
Dose Lung (Gy) 17.27 8.26 
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Patient 2 presented NET metastases involving whole liver. Despite presenting 
pulmonary metastases, the lesions are well defined in CT scan. That way, the ROI to 
delineate the tumor in 99mTc-MAA/SPECT was conducted with the help of a CT scan 
without major difficulties. The obtained results are presented in Table 13. The previous 
calculated activity by BSA method, as well the activity recalculated, this time by PM, 
and the corresponding doses of the normal liver, tumor and lung are also shown in the 
table. 
 
Table 13 - Summary of the characteristics of the case 2. 
CASE 2 
Pathology: Neuroendocrine tumor 
LSF: 6.50 % 
Tumor involvement: 37% 
T/N: 4.72 
 Partition Method BSA Method 
Activity to be administered GBq) 7.40 2.04 
Activity Normal Liver (GBq) 1.84 0.51 
Dose Normal Liver (Gy) 50.00 13.79 
Activity Tumor (GBq) 5.08 1.40 
Dose Tumor (Gy) 236.00 65.06 
Activity Lung (GBq) 0.48 0.13 
Dose Lung (Gy) 23.89 6.59 
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Patient 3 presented a pancreatic cancer with multiple (diffuse) metastases in both 
lobes of the liver. 99mTc-MAA distribution not always reached lesions and presented 
small metastasis with ill-defined margins. This is a problem in PM due to tumor ROI 
delineation. In Table 14 are presented the patient characteristics. 
 
Table 14 - Summary of the characteristics of the case 3. 
CASE 3 
Pathology: Pancreatic cancer 
LSF: 6.90 % 
Tumor involvement: 6.48 
T/N: 34.10 
 Partition Method BSA Method 
Activity to be administered GBq) 6.90 1.92 
Activity Normal Liver (GBq) 1.91 0.53 
Dose Normal Liver (Gy) 50.00 13.96 
Activity Tumor (GBq) 4.51 1.26 
Dose Tumor (Gy) 1704.95 475.88 
Activity Lung (GBq) 0.48 0.13 
Dose Lung (Gy) 23.63 6.60 
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Figure 27 - Relative difference in calculated activities with PM and BSA method as a function of tumor 
involvement.  
 
Figure 28 - Comparison between absorbed doses to tumor obtained from PM and BSA method as a function of 
tumor involvement.  
 
Figure 29 - Comparison between absorbed doses to normal liver and lung obtained from PM and BSA method 
as a function of tumor involvement.  
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The three patients in study received resin 90Y-microspheres with the activity of radiation 
determined by the BSA method. The percentage of microspheres that passes from the 
liver arterial system through to the pulmonary capillary beds was relatively low, with all 
patients presenting a LSF below 20%. Only the patient 1 had a LSF above 10% and 
following the recommendations of Sirtex manufacture, the total activity was reduced in 
20%. In addition, the patient 1 was treated to the right lobe, reducing the activity 
further. The other two patients received the planned activity. 
A major challenge is determining the optimal activity of resin microspheres for an 
individual patient in advance of the procedure. And it is expected that patients may 
benefit greatly from individualized treatment planning. In these three cases under 
study, the partition method was applied to calculate the injected activity and, 
subsequently evaluating the dose which could possibly be delivered to the normal liver, 
lung and tumor. Comparing the initial calculated activity by BSA method with calculated 
activity by PM is possible to verify a considerable difference. In relation to the dose in 
the normal liver was established a limit of 50 Gy for all patients. 
In the first case, a lobar treatment, the calculated activity based on PM is 208% higher 
than BSA activity. Absorbed dose to the tumor is higher in partition method, with 137 
Gy, while with the BSA method the tumor only received 66 Gy. In both cases PM and 
BSA method the dose to the lung was below than 25 Gy. 
In the second case, a whole liver treatment with a tumor with well-defined margins, the 
PM activity is 363% higher than activity calculated using the BSA method. Thus, 
maintaining the limit for the normal liver, in 50 Gy, the absorbed dose to tumor was 236 
Gy based on PM, and only 65 Gy by the BSA method. Once again, the dose to the lung 
has not exceeded the upper limit. 
In the third case, a patient with multiple metastases in the whole liver, the segmentation 
of the tumor and non-tumor liver was complicated. This is because for very small 
tumors may not be possible an accurate delineation of the tumor, harming the T/N ratio 
estimation. Thus, the activity calculated according to PM is 360% higher than BSA 
activity. However, with the result of the T/N ratio, the absorbed dose to tumor is very 
high: 1705 Gy by PM, and 476 Gy from BSA method. In this situation, the BSA method 
should be used given that is suited for small lesions especially with diffuse margins.  
The partition method usually applies to solitary hepatic tumors, although, can also be 
applies in multifocal lesions if each can be adequately localized (Case 1 and Case 2). 
Thus, relatively few metastases will qualify for partition model planning because 
FCUP 
Development of an advanced partition model dosimetry system for hepatic radioembolization 
using 
90
Y-microspheres 
70 
 
accurate partitioning of the tumor compartment and normal liver not always feasible, 
especially in patients with disseminated disease including diffuse, heterogeneous, or 
multiple metastasis (Case 3). However, it is important to keep in mind that the PM 
should be the preferred method for activity calculation of 90Y-microspheres for every 
patient.  
Relative differences in calculated activity with PM and BSA method as function of 
tumor involvement was presented in Figure 27. As well as the absorbed doses by the 
relevant tissues, as tumor (Figure 28), normal liver and lungs (Figure 29), obtained 
from PM and BSA method.  
5.2. Evaluation of Bremsstrahlung imaging  
After radioembolization with 90Y resin microspheres, Bremsstrahlung images of the 
abdomen are obtained using a gamma camera. These images are performed to verify 
the distribution of 90Y-microspheres to the extrahepatic tissue and liver. However, 
Bremsstrahlung imaging suffers from poor resolution. One aim of this study is to 
improve 90Y Bremsstrahlung SPECT images. 
5.2.1. Phantom and Patient study 
SPECT phantom data was acquired using the same protocol for patient acquisition and 
was performed several reconstruction protocols. Table 15 shows the results of the 
reconstruction methods evaluated. 
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Table 15 - Phantom reconstruction parameters.   
Reconstruction 
parameters 
FWHMx 
(mm) 
FWHMy 
(mm) 
Contrast 
(%) 
Noise (%) 
Avoxel 
(MBq) 
FBP, btw, 0.2, 4 20.22 19.98 90.49 0.33 0.74 
FBP, btw, 0.4, 5 13.34 12.89 88.96 0.49 1.20 
FBP, btw, 0.6, 6 13.05 12.51 82.86 0.57 0.93 
2D OSEM, 4i2s 14.45 13.90 89.62 0.26 1.45 
2D OSEM, 8i4s 8.59 8.36 93.74 0.69 3.54 
2D OSEM, 16i8s 5.81 5.98 92.91 1.53 5.62 
2D OSEM, 4i2s,  
6mm Gaussian filter 
15.45 14.90 88.35 0.20 1.31 
2D OSEM, 8i4s,  
6mm Gaussian filter 
9.15 9.10 93.02 0.55 3.04 
2D OSEM, 16i8s,  
6mm Gaussian filter 
6.65 6.76 92.74 0.95 4.60 
2D OSEM, 4i16s,  
10mm Gaussian filter 
9.05 9.10 91.10 0.48 2.83 
2D OSEM, 5i8s,  
10mm Gaussian filter 
9.99 9.96 91.20 0.43 2.45 
2D OSEM, 8i4s,  
10mm Gaussian filter 
10.22 10.34 91.40 0.42 2.33 
2D OSEM, 10i16s,  
10mm Gaussian filter 
7.87 8.10 92.19 0.62 2.97 
2D OSEM, 15i16s,  
10mm Gaussian filter 
7.53 1.98 91.30 0.61 3.57 
2D OSEM, 4i2s,  
12mm Gaussian filter 
17.40 18.12 85.80 0.03 1.01 
2D OSEM, 8i4s,  
12mm Gaussian filter 
11.25 12.08 91.45 0.42 2.03 
2D OSEM, 16i8s,  
12mm Gaussian filter 
8.95 9.14 91.34 0.49 2.72 
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Two algorithms are presented, the FBP and MLEM (OSEM) algorithm. In the FBP 
algorithm was changed the cut-off frequency and the filter order. This algorithm was 
preferred, in clinical practice, because it was computationally faster. However, it has 
several flaws, where to improve the noise compromise image resolution. For example, 
a first application of FBP (0.2, 4) presents a good contrast and noise results, but poor 
resolution (approximately 20 mm). In contrast, to improve the image resolution there is 
a loss of contrast and noise. 
The second algorithm tested was an iterative algorithm requiring also an optimization to 
provide the best trade-off between noise/contrast and image resolution. The OSEM 
algorithm was performed with and without Gaussian filters changing the number of 
iterations and subsets. For reconstructive OSEM method without Gaussian filter with 8 
iterations and 4 subsets present the best trade-off between noise/contrast and image 
resolution. The accuracy increases when applying a Gaussian filter. From Table 15 it is 
still possible to verify that the poor contrast occurs if the number of subsets and 
iterations is small. An increase of the noise level occurs with a higher number of 
iterations. Thus, the noise level in the SPECT images may to be substantially reduced 
when reconstructed with 8 iterations, 4 subsets and Gaussian filter of 10 mm.  
Image contrast and noise is a measure of differences in the counts (activity) 
concentration. Thus the activity per voxel depends on the reconstruction algorithm 
parameters. Increasing the noise also increases the Avoxel.  
Figure 30, Figure 31 and Figure 32 show a transaxial 2D profile from three examples of 
reconstruction parameters. The first is a FBP reconstruction with an image resolution of 
13 mm and some noise. The second example is an iterative reconstruction without 
Gaussian filter, 16 iterations and 8 subsets, which, although presenting an optimal 
resolution and image contrast, have a large noise level. In the last example, the 
reconstruction provides the best trade-off between noise/contrast and image resolution. 
The results of reconstructed images of the patient study are shown in Table 16, Table 
17 and Table 18. For each case in study was applied the reconstruction parameters 
showed in Figure 30, Figure 31 and Figure 32. The liver is clearly seen in the images, 
however, the last reconstruction method, a OSEM with 8 iterations, 4 subsets and 10 
mm Gaussian filter present the best results. 
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.                   
Figure 30 - (I) Representative slice from FBP reconstruction (Bwt, 0.4, 5). (II) 2D plot from axial profile of a 
90
Y 
line source in water. 
              
Figure 31 - (I) Representative slice from iterative reconstruction (2D OSEM, 16i8s). (II) 2D plot from axial profile 
of a 
90
Y line source in water. (III) Comparative Gaussian profile.
              
Figure 32 - (I) Representative slice from iterative reconstruction (2D OSEM, 8i4s, 10mm Gaussian Filter). (II) 2D 
plot from axial profile of a 
90
Y line source in water. 
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Table 16 - Transversal slices of the patient 1 measurement. 
CASE 1 
FBP 0.4, 5 OSEM 16i8s 
OSEM 8i4s, 10mm 
Gaussian filter 
   
Table 17 - Transversal slices of the patient 2 measurement. 
CASE 2 
FBP 0.4, 5 OSEM 16i8s 
OSEM 8i4s, 10mm 
Gaussian filter 
   
Table 18 - Transversal slices of the patient 3 measurement. 
CASE 3 
FBP 0.4, 5 OSEM 16i8s 
OSEM 8i4s, 10mm 
Gaussian filter 
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6. Conclusion and Future Work 
Therapeutic nuclear medicine is developing rapidly as an alternative choice of 
treatment in oncology. Particularly, the radioembolization with 90Y-microspheres has 
been a powerful tool to achieve regional tumor response and disease control in hepatic 
malignancy of various origins. For a long time, has been used a fixed activity or activity 
based in the body surface area. However, caution regarding patient selection, 
treatment preparation including an appropriate dosimetry, and performance is 
particularly important to prevent toxicity to be associated with this treatment. Thus, the 
shift towards personalized radionuclide therapy is an inevitable trend. Stabin for Cancer 
Biotherapy and Radiopharmaceuticals (2008) remarks: Treating all nuclear medicine 
patients with a single, uniform method of activity administration amounts to consciously 
choosing that these patients be treated with a lower standard of care than patients who 
receive radiation externally for cancer treatments 111.  
Using a 99mTc-MAA scan, it is possible to determine the desired activity of 90Y-
microspheres to be injected. In addition, its biodistribution can provide a predictive 
dose distribution within the tumor volume and organs at risk (normal liver and lungs). 
To administer an optimal activity for each patient is needed an improved activity 
calculation method based on accurate physiology parameters. The partition method 
allows calculation of the administered activity in the target volume, the healthy liver 
volume and the lungs. This study included only three cases, but these patients 
represent the cohort of patients indicated for radioembolization. For these patients, 
BSA method remained conservative relative to the activities to be administered, that is, 
the activities obtained by BSA method delivered a sub-therapeutic dose. Meanwhile, 
the PM proposes an activity calculation method that includes patient-specific 
characteristics such as tumor, normal liver and lung volumes and T/N ratio. Thus, the 
accurate radiation dose from PM provides a safe, effective and personalized radiation 
therapy planning.  
In radionuclide therapy, there is the need to measure the distribution of the 90Y, that is, 
through Bremsstrahlung imaging, in vivo, usually performed by SPECT imaging. 
Bremsstrahlung images after radioembolization treatment are useful in evaluation the 
intrahepatic distribution of 90Y and detecting possible extrahepatic activity. To ensure a 
better image quality several reconstruction methods were analyzed. The results 
presented in Table 15 as well as the both phantom and patient studies showed that a 
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trade-off between noise/contrast and image resolution can be obtained with an iterative 
algorithm with a Gaussian filter, 8 iterations and 4 subsets. 
In conclusion, an implementation of the individualized treatment planning is 
fundamental. Thus, the Partition Model is preferable in relation to BSA method because 
it is based on accurate physiologic parameters. Prescription of activity using BSA 
method usually results in an under-treatment in selected patient. 
6.1. Future work 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Figure 33 - Schematic of general procedure of radioembolization. 
SPECT imaging after post-therapy can also be useful for dose verification and 
validation of the treatment planning. Unfortunately, the low photon yield and continuous 
nature of the Bremsstrahlung X-ray spectrum limit the quantitative accuracy of 90Y 
Bremsstrahlung SPECT. 
Future 90Y radioembolization dosimetry techniques are based on today‘s emerging 
technologies. 90Y PET was recently shown to be feasible in phantoms and patients and 
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may be an interesting alternative to Bremsstrahlung SPECT allowing direct imaging of 
90Y-microspheres. Although, 90Y is predominantly a  - emitter, where decays to the 
fundamental level of 90Zr (99.99%), a lower probability branch (0.01%) follows another 
 - decay to the first 90Zr excited state (Figure 34). The following 0+ – 0+ transition 0f 90Zr 
happen via internal par production  -  + with an even smaller branching ratio 
(approximately 32 x 10-6). Although it results in a weak signal, it is detectable by PET 
imaging. 
 
Figure 34 - Simplified decay scheme for 
90
Y.  
The conventional PET scanners, although can be superior over Bremsstrahlung 
SPECT need longer acquisition times for dosimetry calculation due to the loss of 
contrast. In alternative, 90Y PET is feasible with the help of the time-of-flight 
information. The concept of TOF means simply that for each annihilation event, the 
precise time that each of coincident photon is detected and calculated the difference. 
However, PET imaging of 90Y continues to present challenges including attenuation 
and scatter correction. 
In September of 2017, Nuclear Medicine Service of IPO-Porto purchases a new TOF 
PET/CT (Biograph mCT Flow, Siemens Healthcare, Germany) and was possible an 
acquisition of a patient treated for liver using 90Y resin microspheres. Despite of the low 
positron abundance and a low acquisition time (approximately 12 minutes) it 
demonstrates satisfactory results. In the future, improvements in the 90Y PET are 
necessary and indispensable.  
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Figure 35 - 
90
Y TOF PET/CT image. 
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